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Abstract
Breast Cancer is a heterogeneous disease, which affects one in ten women in the UK 
today. Developments in recent years have led to earlier diagnosis and improved
treatments and survival.
However, mortality is still high and metastatic disease remains incurable. 
The role of the immune system in breast cancer has been questioned for over 100
years and more recently has led to major developments most notably in the form of 
Herceptin.
Current evidence suggests that the immune system is stimulated by  
tumours to manifest a response. Many breast cancers show evidence of this immune
response in the form of  tumour infiltrating lymphocytes. However contradictory opinions 
exist as to whether this response is favourable for the host or not. The significance of the
findings of many of these studies is limited by several factors, including small patient
numbers and the fact that qualitative rather than quantitative assessments of tumour
infiltrating lymphocytes have been used.
The aims of this study were twofold:
Firstly, we set out to develop a practical and efficient method for quantifying immune 
responses in tissue specimens and secondly, the main aim was to establish the 
significance of this response, by quantifying the tumour infiltrating lymphocytes in a 
group of patients with breast cancer, using a well designed study.
Our patient group was derived from the Greater Glasgow Health Board database, which 
was established in 1995 to keep a record of all patients diagnosed with breast cancer in
greater Glasgow area.
We designed a case-control study to include patients, who were matched on the basis of 
several factors, recognised as having prognostic significance in breast cancer.
The hypothesis to be tested was that metastatic relapse would be less likely in women 
with breast cancers in which a significant immune infiltrate was present, than in women 
with cancers in which there was no significant immune-cell infiltrate. 
We established a reliable and efficient method for immune cell quantification, which will 
be of value in future studies looking at the immuno-phenotype of the cells that comprise 
the inflammatory cell infiltrate.
Additionally we found that most breast cancers show evidence of an immune cell 
infiltrate and that this response is likely to be protective.13
To date there was conflicting evidence in the literature regarding the significance of the 
immune cell infiltrate in breast cancer. We have confirmed that this immune response is 
likely to favour the host, however we recognise that without knowing the phenotype of 
the cells contributing to this response, further therapeutic developments will not be 
possible.
We now have a well designed dataset of patients on whom to do this in addition to a 
practical and reliable method for cell identification and quantification.
Chapter 1: Introduction
1.1 Background 
Diagnosis and management of breast carcinoma has undergone many changes over the 
past few decades. Mammographic screening is detecting many more, early breast cancers. 
Despite this, and concurrent improvements in treatment, many women still die of breast 
cancer. It remains the commonest malignancy in women worldwide and after non-
melanoma skin cancer is the commonest cancer in the UK. In the UK more than 44,000 
cases of breast  cancer are diagnosed each year (Cancer Research UK 2008). In 
developed countries the incidence of breast cancer has been increasing for many years. 
Over the twenty five year period 1980-2004 the incidence increased by 53%. The 
introduction of the National Breast Screening Programme to the UK in 1988 was 
responsible for a transient additional increase in the incidence of female breast cancer in 14
the 50-64 age. However, the underlying increase in incidence predates screening, and is 
still in evidence today, particularly in older women (Figure 1.1)
Figure 1.1 : Age specific incidence rates, female breast cancer,GB,1975-2004
                    (CRUK)15
Breast cancer is a complex disease with pronounced morphological and biological 
heterogeneity, a tendency to become resistant to chemotherapy, and several different 
molecular pathways. Over the past few years, basic research developments have led to a 
better understanding of the molecular pathology and behaviour of breast cancer. The 
heterogeneity of the natural history and of the response to treatment, of breast cancer 
complicates patient management and influences survival. More recently, several 
biomarkers (steroid hormone receptor and HER2 status) have been added to classical 
pathological data which influence risk evaluation and therapeutic assessments. Evolving 
knowledge of molecular biology and newer techniques, such as genomics and 
proteomics, offer the potential to better define the biology of the disease, both for risk 
assessment and therapy choice. The International Breast Cancer Study Group (IBSG) was 
one of the first groups of investigators to analyze the concept of heterogeneity by 
evaluating the effects of adjuvant chemotherapy in different subgroups: oestrogen 
receptor (ER) rich, ER-intermediate, and ER-low. There is now substantial evidence of a 
greater benefit of chemotherapy in ER-low or ER-negative breast cancer (Henderson et al 
2003, Early Breast Cancer Trialists Collaborative Group, 2005).
It is estimated that one in nine women in the UK will develop breast cancer at some point 
during their lifetime (Office for National Statistics 2007). While there has been an 
increase in the incidence of breast cancer during the 1990s the mortality rate in the UK 
has declined by 20% in the last ten years (ISD Online. Information and Statistics 
Division, NHS Scotland, 2007 and Office for National Statistics 2007) and latest 16
estimates suggest that 64% of those diagnosed with breast cancer today will be alive 
twenty years after diagnosis (CRUK 2007).
Figure 1.2: Age standardised (European) incidence and mortality rates, breast cancer, 
females, GB, 1975-2005 (www.cruk.com)
 
These statistics demonstrate the improved prognosis that advances in prevention, 
detection and treatment have yielded.
However in spite of earlier diagnosis and improved treatments, breast cancer remains a 
major cause of cancer morbidity and mortality. Length of disease-free survival in breast 
cancer is unpredictable, with relapse occurring up to ten years post treatment and even 
beyond. While some of this unpredictability is no doubt determined by tumour factors, it 
is also likely that some is related to host factors, including the immune response of the 
host to the presence of tumour cells.17
1.2 Role of the immune system
1.2.1 Coley’s Toxins
Dr. William B. Coley, an American orthopaedic surgeon, is considered by many today to 
be the father of present day tumour immunotherapy. In 1888, Coley was inspired by the 
unexpected complete recovery of a patient, terminally ill with a malignant bone tumour, 
following an attack of erysipelas (Cancer Research Institute 1976). He inferred from this 
event that the host response to a bacterial infection, in this case, with Streptococcus 
pyogenes, had also suppressed tumour progression. In 1891, he injected streptococci into 
a patient with an inoperable cancer, following which this tumour also underwent 
regression. Using a bacterial vaccine to treat primarily inoperable sarcoma, Coley 
achieved cure rates better than 10% (Coley 1893). He continued to use bacteria as a 
treatment  in cancer patients for the next few decades, refining his method by mixing   
streptococcal toxins with those of Bacillus prodigiosus (now called Serratia   
marcesens).This increased tolerability for the patients. The reported results were best in 
bone and soft tissue tumours. This treatment came to be known as ‘Coley’s toxins’.    
M.J. Shears, in 1943, discovered that the biologically active substance in Coley’s toxins 
is lipo-polysaccharide (LPS), which is found in cell walls of gram-negative bacteria 
(Ward 1988). However, opinion within the medical community was not always 
supportive. James Ewing, who first described the bone tumour that was to be later named 18
after him, was an enthusiast for radiotherapy, and was especially opposed. Gradually 
Coley's treatment lost favour. Coley's toxins were produced commercially for many years 
with some reported successes but production ceased by the mid 1950s. Other studies 
analyzing their effects in humans and mice were on the whole favourable (Havas 1960 & 
1990) and in the 70’s various trials of mixed bacterial vaccines (MBV) – as Coley’s 
toxins are now called - were carried out (Zhao 1992). The evidence from the clinical 
research that has examined this early form of cancer immunotherapy is limited by the 
small number of cases and the research methods used in the early 20th century. Some 
studies found that Coley's toxins did improved survival in certain forms of cancer, while 
others did not find significant benefit compared with more orthodox combined 
approaches (Chandler et al 1965). Modern forms of immunotherapy based on a better 
understanding of the effects of the immune system on cancer may ultimately prove more 
effective.   
1.2.2 Paul Ehrlich. 
The role of immunological function in the pathogenesis and progression of breast cancer 
has been under investigation for many years and remains an active field. The concept of 
an immunological mechanism directed against autologous cancer cells was first proposed 
by Ehrlich at the beginning of the last century (Ehrlich 1900). In 1909 Ehrlich suggested 
that the immune system could suppress tumour development, and proposed that the 
incidence of cancer would be much greater if not for the ability of the immune system to 
identify and eliminate nascent tumour cells (Silverstein 1999).  Ehrlich also pre-empted, 
by 50 years, the theories of Jerne and Burnet on antibody formation. He postulated that 19
all physiologically active substances, antigens, function by attachment to preformed 
receptors or surface immunoglobulins on a cell, resulting in the release of the
receptor and its regeneration by the cell. These receptors are released into the circulation
as antibodies (Schwarz 2003).
                                           
Figure 1.3: Ehrlich antigen receptor theory (https://savoypharmaceuticals.com/
images/receptor.jpg)
However there was scepticism about his theory because of its implication that the 
immune system has the ability to generate unique receptors to an array of antigens before 
it is even exposed to them. Interest in this area was renewed in the middle of the 
twentieth century when studies in mice demonstrated an immune response capable of 
recognising and destroying transplanted tumour. However the underlying mechanism was 
thought to be one of allograft rejection, rather than being tumour specific.
1.2.3 Immune Surveillance. 
In the 1950s the idea of ‘immune surveillance’ preventing the emergence of neoplasia 
was revived by Burnett and Thomas (Burnett 1957, Thomas 1959). Like Ehrlich, they 
believed the immune system had a role in control of carcinogenesis and that it could 
recognise and destroy nascent tumour cells. Central to their theory was the discovery of 20
tumour specific antigens. These were identified through studies showing that mice could 
be immunised against syngenic transplants of tumours induced by chemical carcinogens 
or viruses (Old et al 1964, Klein 1966). Burnet (1970) stated “ …It is an evolutionary 
necessity that there should be some mechanism for eliminating or inactivating potentially 
dangerous mutant cells and it is postulated that this is of immunological character”. 
They postulated that lymphocytes were responsible for recognising incipient cancers 
(Burnett 1970). Studies seeking to challenge immune surveillance, by experimentally 
inducing immuno-suppression in animal models were inconclusive (Kaplan 1971, 
Stutman 1975), but following studies by Osias Stutman of athymic nude mice immune 
surveillance fell from favour. He demonstrated that these mice did not develop more 
chemically induced tumours when compared with their wild-type counterparts (Stutman 
1973, 1979). It is, however, now known that nude mice do in fact possess some 
functional T cells and in particular also possess NK cells, so they are not completely 
immuno-compromised (Maleckar et al 1987) and these cells may well have a role in 
preventing tumour progression in nude mice. 
1.2.4 Recent Developments
It was not until the 1990s that further developments led to revived interest and renewed 
support for a significant role for the immune system in controlling tumour development. 
Both Interferon   and Perforin, two important components of the immune system, were 
key to this. Endogenous interferon   (IFN  ) was found to protect a host animal against 
transplanted, chemically induced and spontaneous tumours (Shankaran et al 2001). 
Perforin, a component of the cytolytic granules of cytotoxic T cells and natural killer 21
(NK) cells, was found to be an important mediator of lymphocyte-dependent of tumour 
cell killing (Russell et al 2002). Perforin deficient mice were more susceptible to 
chemically induced tumours than their wild-type counterparts. The development of mice 
with genetically defined mutations causing immunodeficiency allowed experiments 
conclusively demonstrating an increased risk of chemically induced and spontaneous 
epithelial tumours (Shankaran et al 2001). It is currently believed that T-cell mediated 
immunity evolved as a protection against infections (Zinkemagel et al 1979). The original 
theory of immune surveillance proposed the involvement of systemic, antigen-specific T-
cell mediated immune responses of the type responsible for allograft rejection. Clinical 
studies have since confirmed that T-cell mediated immunity does indeed have a critical 
role in the development, progression and metastatic spread of cancer (Puisieux et al 1996, 
Topalian et al 1994). The tendency for immunosuppressed organ transplant recipients to 
develop malignancies supports this idea (Kliem et al 1997). It is significant that these are 
often tumours in which a viral aetiology is suspected or likely, such Epstein-Barr driven 
non-Hodgkin’s Lymphoma (Penn 1999). However, an increased incidence of tumours of 
non-viral origin following organ transplantation has also been reported from several 
centres (Penn 1999, Birkeland et al 1995). Data from both clinical and studies in mice 
support the idea that immunosuppression, whether congenital or acquired is associated 
with malignancy (Gattie et al 1971, McClain 1997). Additionally there are several reports 
in the literature describing spontaneous regression of breast and other cancers. Some of 
these tumours were heavily infiltrated with lymphocytes (Van den Hove et al 1997). In 
these cases the mechanism of tumour destruction is presumed to be immunologic (Finke 22
et al 1994). Conversely, many tumours, even with heavy infiltration of lymphocytes do 
not spontaneously regress and in melanoma, histological evidence of regression is not 
associated with improved prognosis. The immune system can also potentially allow 
tolerance to develop or tumours may be able to escape from surveillance, so in spite of its 
known ability to destroy tumour cells, the immune system is not 100% successful as 
shown by tumour development in individuals who are immuno-competent. Recently the 
term ‘immunoediting’ has been coined to describe these paradoxical functions (Dunn et al 
2002). Immunoediting is illustrated in Figure 4. This process is responsible for both 
eliminating tumours and 'sculpting' the immunogenic phenotypes of those tumours that 
do eventually form in immunocompetent hosts. 
Figure 1.4: The three Es of cancer immunoediting: host protective versus  tumour  
                   sculpting actions of immunity 
                   (Dunn et al, Immunity, 2004)23
A developing tumour is detected by the immune system, following cellular 
transformation and the failure of intrinsic tumour suppressor mechanisms. According to 
Dunn et al (2004), it faces several potential outcomes, depending on the host response. 
They proposed that one of the three things that could happen: 1) Elimination phase. Host 
immunity initiates its protective mode and eliminates the tumour. 2) Equilibrium phase: 
the tumour is maintained or permitted to persist in a dormant state. 3) Escape phase: the 
tumour evades the tumour suppressor actions of the immune response either by becoming 
non-immunogenic, or by elaboration of immunosuppressive molecules and cells. 
Others have also shown that the immune system can influence the immunogenicity of a 
developing tumour. In recent years a number of studies in mice have shown that, in the 
absence of an intact immune system, developing tumours are more immunogenic than 
those arising in an immunocompetent host (Shankaran et al 2001). Numerous innate and 
adaptive immune effector cells and molecules participate in the recognition and 
destruction of cancer cells during cancer immunosurveillance. But cancer cells can avoid 
immunosurveillance through outgrowth of poorly immunogenic tumour-cell variants 
(immunoselection) and by subversion of the immune system (immunosubversion). 
During early stages of carcinogenesis, cell-intrinsic barriers to tumour development seem 
to be associated with stimulation of an active antitumour immune response, whereas 
overt tumour development seems to correlate with changes in the immunogenic 
properties of tumour cells. Immunogenic chemotherapy to re-establish anti-tumour 
immune responses could increase the chance of permanent success of treatments for 
cancer. 24
1.3 Tumour Infiltrating Lymphocytes
1.3.1 Background 
Tumour infiltrating lymphocytes (TILs) are a manifestation of the immune response to 
tumours that have been increasingly researched in recent years. Tumour infiltrating 
lymphocytes are a common feature of many malignant neoplasms (Rosenberg et al 1986 
& Marrogi 1997). Previously, their presence was taken as evidence of a host response 
against the developing tumour. More recent research suggests that tumours are recognised 
as self and lack strong foreign antigens. As Dunn (2004) suggested, it is thought that a 
tumour may be selected to manipulate the host immune system to prevent rejection. Their 
significance, however, remains controversial. Studies looking at TILs in melanoma and 
ovarian cancer have demonstrated that when present at high density, they are associated 
with an improved prognosis (Clark et al 1989, Curiel et al 2004)) but equally there are 
data correlating a high density of TILs with a poor prognosis (Coussens et al 2001& 
2002). There are conflicting reports as to how exactly TIL density impacts on outcome in 
breast cancer, if at all (O’Sullivan et al 1994, Naukkarinen et al 1990). This idea that 
lymphocytes may actually facilitate cancer progression has been encouraged by the fact 
that some cancers are caused by infectious agents e.g. viruses that might cause chronic 
inflammation (Coussens et al 2002) or arise in the context of chronic inflammation. 
Approximately 50% of breast cancers have evidence of a lymphocytic infiltrate (Bilik et 
al 1989). Two studies in the last decade have demonstrated an association between a 25
lymphocytic infiltrate and improved outcome in certain subgroups of patients (Menard et 
al 1999, Pupa et al 1996). A dense lymphocytic infiltrate was associated with 
substantially improved survival in the short and long term. More recently a larger study 
by Lee et al (2006) demonstrated an association between a lymphocytic infiltrate and 
better prognosis on multivariate analysis. However, this improved outcome was seen only 
in patients under age 40 at the time of diagnosis. Medullary carcinoma of the breast 
(MCB), a morphologically and biologically distinct subtype of human breast cancer, has 
a diagnostic lymphoplasmacytic infiltrate. Despite cytologically anaplastic features, 
which would normally imply poor prognosis, there is some evidence for a better outcome 
than matched cases of infiltrating ductal carcinoma (Pederson et al 1991) and it has been 
proposed that its more favourable outcome may be a consequence of the prominent 
lymphoplasmacytic infiltrate. Several studies have shown that long term survival in MCB 
correlates with the intensity of tumour infiltration by these cells (Underwood 1974). 
However not all the evidence is in agreement. Rosen et al (1989) found an intense 
peritumoral lymphoplasmacytic infiltrate was associated with a poor prognosis. Other 
studies have shown no association at all (Aaltoma et al 1992). 
Figure 1.5 illustrates the immune infiltration that may be seen in breast carcinoma (black 
dots) in comparison to the relative lack of it in normal breast tissue. 26
Figure 1.5: Development of human breast carcinoma is sometimes characterized by 
abundant infiltration of immune cells. Representative sections of normal, premalignant, 
and malignant human breast tissue stained with haematoxylin and eosin (H&E) (upper 
panels), and following immunodetection of CD45 (leukocyte common antigen, brown 
staining). (DCIS, ductal carcinoma in situ)
DeNardo and Coussens 2007   
1.3.2 T Cells 
More recently the focus has been on the type, rather than the quantity, of infiltrating cells. 
It is now thought the composition of the infiltrate may have a greater influence on 
prognosis. For example, T regulatory cells (CD4+ CD25+ T reg cells) may impair host 
defences against malignancy (Shimizu et al 1999, Jones et al 2002). T cells display wide 
diversity of phenotype, function and anatomical distribution. In terms of function they 
may be effector, regulatory or suppressor. Effector T cells are tightly controlled by 
various regulatory cells including dendritic cells, regulatory T cells and suppressor cells 
via secretion of inhibitory cytokines or contact mediated inhibition. (Kaplan 1971, 
Stutman 1975). Studies have suggested that suppressor T cells play a key role in the 
progression of cancer (North et al 1984, Awwad et al 1988). Many mice studies have 27
demonstrated T cells to be effectors in tumour immunity. Mice depleted of T cells are 
more susceptible to UV light induced tumours (Ward et al 1990) and there is some 
limited evidence from human studies of their importance. Recent clinical trials of 
adoptive transfer of in vitro expanded TILs in combination with chemotherapy have 
demonstrated a 50% positive response rate in selected patients with advanced aggressive 
tumours (Rosenberg 2001 & 2004). Most tumour infiltrating T cells are CD 4+ or CD 8+ 
(Marsigliante et al 1999, Chin et al). CD8+ T cells are cytotoxic lymphocytes (CTLs) 
which can induce tumour killing when presented with the tumour’s MHC class 1 
molecules. Most tumours are positive for MHC class 1 molecules. Cytotoxic T 
lymphocytes are one of the principal cells of the anti-tumour response in murine studies. 
In UV light induced tumours the CD8+ cells are required for tumour rejection (Ward et al 
1990) and this has been confirmed in adoptive transfer studies, of in-vitro stimulated 
CD8+ lines, in humans (Rosenberg 2004). CD4+ T cells are also central to immune 
responses. They also can recognise tumour antigens and migrate to the site of a tumour in 
both murine and human cancers (Pardoll et al 1998). However, there is evidence that 
these cells can actually hinder activity of the CD8+ cells (Berendt et al 1980, Wang et al 
2004). This effect is attributed to CD4+CD25+ T regulatory cells (Dieckmann et al 
2001). CD 4+ cells can also eliminate tumour cells in the absence of CD8+ cells (Beatty 
et al 2001). However, they work more effectively together (Beatty et al 2000). This is 
partly because the absence of MHC class II molecules from a substantial number of 
tumour cells limits recognition by CD4+ T cells which are thought to function largely 
through activation of CD8+ T cells. 28
1.3.3 T Helper Cells
 T helper (Th) cells are central to the amplification and regulation of cellular immune 
responses against infection and possibly malignancy. These are also CD4+ cells, which as 
mentioned recognise antigenic peptides presented with MHC class II molecules. These 
antigens are taken up by specialised antigen presenting cells (APC) and the resulting 
processed peptides exposed in MHC class II at the cell surface. This process is called 
cross presentation and is illustrated in figure 1.6 
   
  Figure 1.6: Viral subversion of dendritic cell function: cross priming is required to 
generate CTL immunity. Nature Reviews Immunology, November 2001
T helper cells become functional via the interaction between APC cells, such as dendritic 
cells and the CD4+ T cells. This combined with resulting release of cytokines contributes 
to the outcome of the cellular immune response. T helper cells can be divided into 29
different types according to their cytokine profile (Mosmann et al 1996). Type 1 cells are 
characterised by the production of IFN  and interleukin-2 (IL-2) amongst others. Type 2 
cells produce other cytokines including IL-4, -5 and -10, which can cross-regulate each 
other’s function and development (O’Garra 1998). The cytokines play a role in the 
outcome of both cellular and humoral immune responses. The T helper cells activate 
antigen-specific effector cells including CTLs and B cells and can recruit other immune 
cells such as mast cells and macrophages (Kalams et al 1988, Ossendorp et al 2000). In 
2002 Dudley et al evaluated the therapeutic efficacy of adoptive T cell therapy in 
malignant melanoma patients. There was evidence of tumour killing and that CD4+ T 
helper cells were central to this.
1.3.4 B Cells
Most studies in the literature to date have concentrated on T cell processes. B cells, while 
not so numerous as T cells in tumour lymphocytic infiltrates, are still potentially 
significant. One study, which examined a variety of tumours, found that anti- tumour 
antibodies were produced by tumour-infiltrating B cells in approximately 70% of cases 
(Punt et al 1994). Approximately 20% of invasive breast cancers contain significant 
numbers of B cells, with B cells constituting up to 60% of TIL in some cases (Coronella 
et al 2001, Grekou et al 1996). Several studies have found that when present CD 20+ TIL 
B cells occur in follicle-like aggregates. This is consistent with an in situ antigen-driven 
response generating anti-tumour antibodies. Nzula et al, 2003, confirmed this and have 
shown that it is accompanied by clonal proliferation and somatic hypermutation of 30
immunoglobulin V- genes, similar to the germinal centre response in sentinel lymph 
nodes. Preliminary data suggest that these B cells are responding to tumour antigen. 
Furthermore, recent work using a transgenic animal model of breast cancer has 
demonstrated that B cells and antibodies play an important role in the elimination of 
tumours . Immunisation of mice with three different types of tumour antigen preparation 
induced a protective immune response against development of transplanted or 
spontaneous mammary carcinomas (Renard et al 2003, Curcio et al 2003, Nanni et al 
2004, Park et al 2005). This protective response was B cell, but not T cell, dependent. 
1.3.5 Dendritic Cells
 Another group of cells thought to be important for the immune response in tumours, are 
dendritic cells. These potent antigen-presenting cells play a major role in initiating anti-
tumour immune response. While they are found in varying quantities in breast cancer, 
they are absent from normal breast tissue (Hillenbrand et al 1999). A similar situation 
exists for MHC class II molecules (Bartek et al 1987, Moller et al 1989). High tumour 
infiltrating dendritic cell (TIDC) densities are associated with a favourable prognosis in 
some tumour types (Wright-Browne et al 1997). A mouse study in 1997 found that active 
immunisation using dendritic cells mixed with tumour cells inhibited growth of primary 
breast cancer (Coveney et al 1997). Tumour antigens may either be presented by MHC 
class II expressing tumour cells or by actual antigen presenting cells attracted to the 
tumour site (Qi et al 2000). An intense inflammatory infiltrate may induce tumour MHC 31
II expression via release of cytokines. Dendritic cells may in this way favour the 
generation of tumour specific effector T cells and could therefore be associated with a 
more pronounced immune response. A study of 40 breast cancers showed a correlation 
between tumour MHC II expression and an associated inflammatory infiltrate containing 
CD1a+ dendritic cells (Hillenbrand et al 1999) and an association between p53 over-
expression and the presence of immature dendritic cells. 
1.4 Mechanisms of Tumour Killing: Humoral Immunity
1.4.1 Antibody Dependent Cellular Cytotoxicity (ADCC)
ADCC is an effector mechanism against tumour and virus-infected cells. They are 
destroyed by the combined action of specific antibodies of the IgG isotype directed 
against cell surface antigens, and effector cells, predominantly of the Natural Killer (NK) 
cell phentotype. ADCC requires three components: 1) target cells expressing tumour 
antigens on their surface; 2) IgG antibodies against the target antigen; and 3) effector 
cells bearing Fc gamma receptor (Fc R)(Clynes et al 2000). The antibodies, having 
recognised the antigen on the target cell, bind to it. Fc receptors on immunocompetent 
cells recognize the Fc portion of antibodies bound to tumour surface antigens (Figure 4). 
Most commonly the effector of ADCC is a natural killer (NK) cell. Following recognition 
and attachment via its Fc receptors, the NK cell can destroy the target cell through release 
of granules containing perforin and granzyme B and/or activation of the Fas/Fas ligand 32
apoptosis system in the target cell. Perforin molecules make holes or pores in the cell 
membrane, disrupting the osmotic barrier and killing the cell via osmotic lysis. The 
existence of ADCC has been verified in recent times by the introduction of a number of 
therapeutic unconjugated antibodies which are used to manipulate the host immune 
response to tumour. Most notable has been the advent of Herceptin.
                
                Figure 1.7: Antibody-Dependent Cell-Mediated Cytotoxicity. Naylor 2001
1.4.2 Herceptin (anti-HER2/neu antibody) 
Herceptin is an antibody used to target the her2/neu gene. Her2/neu, a member of the 
human epidermal growth factor receptor family, is amplified in approximately 25% of 
invasive ductal carcinomas of breast. Amplification is associated with aggressive 33
behaviour and reduced survival (O’Sullivan et al 1994). Herceptin mediates ADCC in 
vitro and is postulated to do so in the clinical setting (Baselga et al 1996, Slamon et al 
1998). Herceptin is directed against the extracellular domain of the her2/neu protein. 
Clinical trials have demonstrated that it prolongs the survival of patients with metastatic 
her2/neu over-expressing breast cancer in combination with chemotherapy and has 
recently been demonstrated to lead to dramatic improvements in disease-free survival in 
the adjuvant therapy setting, in combination with or following chemotherapy. Herceptin 
in combination with chemotherapy produces longer time to progression and improved 
survival (Piccart-Gebhart et al 2005)
1.5 Mechanisms of Tumour Killing: Cellular Immunity
1.5.1 Cellular Immunity 
Cellular immunity comprises adaptive and innate components, both of which have a role 
in mediating tumour immunosurveillance (Rosenberg 1997, Banchereau 1998)). The 
adaptive component depends mainly on CD4+ and CD8+ T cells (Rosenberg 1997), which 
are primed by dendritic cells (DC)(Banchereau 1998) and recognize tumour antigens 
presented by major histocompatibility complex (MHC) class I molecules on tumour cells. 
Cytotoxic T lymphocytes (CTLs) are essential for host defences against both pathogenic 
micro-organisms and malignant cells (Russell et al 2002). The T cell receptor (TCR)-
major histocompatibility (MHC)-peptide complexes are the cell surface molecules 
involved. When CTLs recognise target cells, the TCR on the CTL surface combines with 
MHC molecules. Specific cytotoxicity requires T cell receptor recognition of tumour-34
associated antigens presented in the context of the MHC molecules and in addition a 
number of accessory molecules which mediate both target binding and delivery of 
additional regulatory signals. T cells are unresponsive or anergic when the TCR is 
occupied in the absence of a costimulatory signal (Schwartz et al 1996). However, 
according to Kuwano et al (1998), they are still capable of causing tumour cell death even 
in the absence of cytokines which anergic CTLs do not release. T cell-mediated toxicity 
results in unidirectional lysis of the target cell.
The innate component of cellular immunity to tumours has been attributed largely to 
natural killer (NK) cells, which can also lyse tumour cells (Banchereau et al 1998). NK 
cells achieve their lytic functions via perforin/granzyme, CD95 ligand (FasL) or tumour 
necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) pathways, depending 
on the cytokines NK cells respond to, and on the expression patterns of NKG2D ligands 
on tumour cells (Smyth et al 2003). Recent studies have substantiated a pivotal role of 
NK cells, perforin, and IFN-  in natural protection from primary tumour development 
induced by the chemical carcinogen methylcholanthrene (MCA) (Street et al 2001). 
1.5.2 TNF- Related Apoptosis-Inducing Ligand (TRAIL Pathway)
 TRAIL, also known as Apo2 ligand, is a type II transmembrane protein of the TNF 
super-family. At least five receptors for TRAIL have been identified in humans (only one, 
DR5 [TRAIL-R2] in mice) and two of them, DR4 (TRAIL-R1) and DR5, are capable of 
transducing an apoptotic signal (Degli-Esposti 1999, Ashkenazi 2002). Controversy 35
exists over the intracellular signalling pathways responsible for TRAIL receptor-induced 
apoptosis. Most recent studies suggest DR5 signals through FADD- and caspase-8-
dependent pathways (Bodmer et al 2000). A clear role for TRAIL, in the T cell-mediated 
immune defence against tumour, has been demonstrated in recent years (Schmaltz et al 
2002).  
Figure 1.8: TRAIL pathway (Smyth et al 2003) 
Allogeneic hematopoietic cell transplantation (AHCT) is an important therapy for a 
variety of malignant diseases. The anti-tumour activity of allogeneic donor T cells (graft 
versus tumour, GVT) provides evidence for T cell mediated anti-tumour activity with 
clinical relevance and is at present the most potent immunotherapy of cancer available. 
GVT activity is triggered by the recognition of tumour-specific antigens expressed on 
malignant cells. Several mouse bone marrow transplantation (BMT) models have shown 
the TRAIL pathway to be a prerequisite for optimal GVT activity by donor T cells 36
(Schmaltz et al 2002). It has also been shown that the TRAIL pathway can selectively kill 
transformed cells preferentially over normal cells. Although the only NK cell subset to 
express TRAIL constitutively is restricted to the liver, many NK cells in the lungs, liver, 
and spleen can be induced to express TRAIL by interleukins-2 (IL-2) or -15 and 
interferons (IFNs), and then kill tumour cells in vivo through a TRAIL-dependent 
pathway (Smyth et al 2003, Kayagaki et al 1999). 
1.5.3 Perforin 
Perforin is a pore-forming toxic protein synthesized and stored in cytoplasmic vesicles of 
cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. It is secreted when these 
effector lymphocytes encounter virus-infected or neoplastic cells (Trapani et al 2007) and 
has a role in tumour cell killing. This has been demonstrated by several authors eg Smyth 
et al (2000) who demonstrated that perforin-deficient mice were more prone to 
spontaneous NK cell tumours. Thus it can be deduced that perforin is an important 
immune effector molecule (Jaatela et al 1995). Like perforins, granzymes (Baselga et al 
1996) are lytic cytoplasmic granules found in CTLs and NK cells. They stimulate 
formation of pores in target cell memebranes which  not only cause osmotic lysis but may 
also initiate the apoptotic process (Henkart 1985). These granules are thought to be 
released following receptor-mediated binding of target cells by NK cells or CTLs which 
stimulate a Ca++- dependent degranulation by the effector cell. The released perforin/
granzymes then lead to target cell lysis. Most studies have concentrated on demonstrating 
the presence of perforin and granzymes in activated lymphocytes and correlating their 
presence with cytotoxicity (Darmon et al 1995, Froelich et al 1996). There is evidence 37
that perforin is a marker for cytolytic activity but that does not necessarily mean it is 
directly involved in target cell killing. Until recent years there was also a lack of evidence 
for the role of granzymes in cell killing. Granzymes and perforin may work together to 
produce cell death: it has been suggested that granzymes released along with perforin 
travel via perforin-induced pores to the target cell cytoplasm where they induce apoptosis 
(Lieberman et al 2003) and some investigators believe that granzyme activity requires 
perforin. Several groups (Shivers et al 1992, Nakajima et al 1995) have found that 
transfection of cells with granzymes alone does not lead to target cell death. However 
when the same cells are transfected with perforin, cell death was induced. 
Recently, studies using gene-targeted mice have demonstrated an important role for 
perforin in tumour immunity. Perforin was initially shown to play a broad role in 
protecting the host from experimental tumour challenge and from tumours initiated by 
some carcinogens (Van den Broek et al 1996) and it has since been shown that perforin is 
involved in inducing the anti-metastatic activities of NK cells against a variety of non-
lymphoid tumours, including breast carcinomas (Smyth et al 1999, 2000). It has been 
suggested that aggressive tumour variants may escape from cytotoxic T cell (CTL) attack 
by down-regulating Fas, rather than becoming perforin-insensitive (Kagi et al 1994). 
1.5.4 Fas/Fas Ligand.
Fas is a transmembrane receptor that belongs to the tumour necrosis factor (TNF) family. 
It can induce apoptosis after cross-linking with either agonistic antibodies or with Fas 
Ligand (Fas L). Fas ligand is expressed on the membranes of activated B and T cells, in 38
addition to several organs and tumour cells (Locksley et al 2001). Much of the literature 
suggests that CD4+ cells, which frequently lack perforin-containing cytoplasmic 
granules, kill target cells through a Ca++ independent Fas-mediated mechanism (Lancki 
et al 1991). About a decade ago, the death factor Fas L was identified as the natural 
trigger of Fas/CD95-dependent apoptosis and as an inducer of Fas-dependent activation-
induced cell death. It is now known that this molecule not only contributes to target cell 
lysis in the immune system but also to the establishment of immune privilege and tumour 
survival (Igney et al 2005). 
There is increasing evidence that Fas/Fas L have an important role in tumour 
development. Not only are they involved in promoting apoptosis but there is evidence to 
suggest they can activate numerous non-apoptotic signalling pathways, leading to 
increased tumourigenicity and metastasis (O’Brien et al 2005). It has also been 
demonstrated that apoptotic killing may result in reduced tumour immunogenicity 
compared with lytic mechanisms which induce heat shock protein and produce 
inflammation (Melcher et al 1998). This is because apoptotic bodies are efficiently 
removed by phagocytosis without a significant inflammatory response. Therefore, 
mechanisms of tumor lysis may influence outcomes of immune responses to tumours and 
impact on how such responses might be manipulated. Rouvier et al (1993) demonstrated 
that murine cells transfected with Fas became susceptible to CTL-induced apoptosis 
when previously they had been resistant. In contrast to the calcium-dependent perforin 
pathway, Fas requires target cells to be in a susceptible state for apoptosis (Alderson et al 
1993 ). Jaatela et al (1995) demonstrated that overexpression of bcl-2 or bcl-x can block 39
Fas- mediated cytotoxicity. This may be a mechanism by which tumours can overcome 
natural cytyotoxic pathways. The BCL2 genes regulates cell death by affording 
protection against apoptotic signals. On the other hand, CTL and NK cells are 
heterogeneous, and may have more than one method of destroying target cells.
1.5.5 Cytokines
Cytokines are inducible chemical messengers produced by a variety of cells throughout 
the body. They are low-molecular weight glycoproteins involved in inflammatory and 
immune responses (Dinarello 2000). They are secreted by healthy and diseased cells and 
act on many different target cells. Cytokines regulate cell survival, growth, 
differentiation, and effector functions (Heinrich et al 1998). Unsurprisingly tumour 
growth in vivo is influenced by cytokines. They may act as tumour promoters or 
inhibitors and can be pro- or anti-inflammatory. Cytokines, as mediators of the effector 
response from innate and acquired cellular immunities (Abbas et al 1994), are probably 
involved in tumour cell evasion of immunosurveillance. 
1.5.6 Interleukins
Interleukins (IL) and tumour necrosis factor are familiar cytokines. The interleukin (IL) 1 
family of cytokines (IL-l , IL-1 ), is frequently expressed in breast cancer cell lines, in 
human breast cancer tissue, and in the tumour microenvironment (Miller et al 2000, 
Pantschenko et al 2003, Singer et al 2003). Similarly, high concentrations of IL-6 have 
also been found (Liu et al 2002, Honma et al 2002, and Kurebayashi et al 2000). Several 
cell types including lymphocytes (mainly Th2 cells) are thought to be an important 40
source of IL-6. IL-6 promotes tumour growth by up-regulating anti-apoptotic and 
angiogenic proteins in tumour cells (Heinrich et al 1998, Knupfer et al 2004, Sabbioni et 
al 2000). 
IL-2 has been one of the most commonly studied cytokines in clinical trials. It has been 
shown that higher serum values of soluble IL-2 receptors are associated with favourable 
prognostic factors, including ER positivity (Zhang et al 1999). In several studies of 
metastatic breast cancer, multivariate analysis identified high serum IL-6 levels as an 
independent adverse prognostic variable for disease-free and overall survival (Bachelot et 
al 2003, Colombo et al 2002). In vitro many cytokines have a therapeutic anti-tumour 
effect. To date, however, IL-2 and IFN  are the only cytokines approved for oncological 
use (Gresser et al 1969). IL-2 has been used in clinical trials of patients with advanced 
breast cancer both with IFN  and in conjunction with Herceptin (Meehan et al 1999, 
Kimmick et al 2004, Flemming et al 2002). While it was well tolerated, the benefits have 
not been impressive. Median overall survival was improved in only one study (Nicolini et 
al 2005). 
1.5.7 Tumour Necrosis Factor
Members of the tumour necrosis factor (TNF) family of cytokines are expressed by 
effector lymphocytes and are important mediators of apoptosis that both shape and
regulate the immune system.
Tumour necrosis factor alpha (TNF ) is a cytokine that acts as an important mediator 
of the apoptotic process that also demonstrates selective cytotoxicity against breast 
cancer cells.(Park et al 2002,Fujiki et al 2002,Basu et al 2001).41
It is mainly produced by macrophages and T lymphocytes. Various studies have 
examined its anti – tumour potential and role in recruiting the immune system to 
defend against malignancy (Bower et al 2002, See et al 2002).
Higher TNF – alpha secretion however has been found in solid tumours and appears 
to be closely linked to the development of metastasis.(Ardizzoia et al 1992).
Recently its been demonstrated that co-cultivation of breast cancer cells with 
macrophages leads to increased invasiveness  of the malignant  cells due to 
TNF – alpha- dependent up regulation of metalloproteases (Hagemann et al 2004).
1.5.8 Interferons
Interferon (IFN) was originally identified by Isaacs and Lindenmann in 1957, when they 
discovered that it was released following the incubation of heated virus with membranes, 
and demonstrated its ability to interfere with viral replication. In 1969 Gresser et al 
demonstrated that treatment with IFN can inhibit tumour growth in animals. IFNs are 
now recognized as central regulatory mediators of the immune response. Their functions 
of include anti-tumour and immuno-regulatory activities. Interferons   and   are type I 
IFNs with antitumor activity (Abbas et al 1994). They down-regulate oncogene 
expression and induce tumour suppressor genes which result in anti-proliferative activity. 
They also increase expression of MHC class I molecules in tumour cells, which can 
enhance immune recognition (Belardelli et al 2002). Recent studies have identified 
additional immunological effects of IFNs. They can stimulate proliferation and prolonged 42
survival of human cytotoxic lymphocytes. Dendritic cell function is also promoted via 
their activity (Belardelli et al 2002). Moreover, in clinical trials on melanoma and renal 
cell carcinoma, IFN  increases both NK cell and T helper lymphocyte activity, as well as 
in-vitro T-cell responses and tumour infiltrating lymphocytes numbers (Belardelli et al 
2002). 
1.6 Tumour Infiltrating Lymphocytes and Prognosis
There have been numerous studies over the last few decades analysing the lymphocytic 
infiltrate found within breast and other cancers. Many of these studies have examined the 
relationship between intensity of this infiltrate and the eventual outcome of the tumour 
(Marsigliante et al 1999, Bassler et al 1981, Ogmundsdottir et al 1995). The results have 
been conflicting. Some studies suggest that an intense infiltrate represents an active 
immune response against the tumour, and is therefore a favourable prognostic sign (Rilke 
et al 1991). Conversely, others have suggested that an immune response of this nature is 
associated with a poor prognosis (Parl et al 1982) while others again suggest there is no 
link between inflammation and outcome (Roses et al 1982, Alderson et al 1971). 
However, there have been limitations with many of these studies. Many have been 
observational studies only of relatively small case numbers. There have also been many 
studies looking at phenotypes of various tumour-infiltrating cells but their value has often 
been limited by purely qualitative assessment. In the absence of conclusive findings 
investigations of the search for the clinical significance of tumour infiltrating 
lymphocytes continue.
1.7 Immunotherapy43
1.7.1 Background
Cancer immunotherapy has developed as an additional treatment modality in the 
management of breast cancer. Two major strategies have been explored. Firstly, the 
application of monoclonal antibodies, such as Herceptin, directed against tumor-
associated antigens; and secondly, cancer vaccines targeting breast cancer antigens 
through the patient's own immune system.
1.7.2 Tumour Antigens
Ultimately, the main practical aim of examining tumour immune responses is to identify 
means of manipulating such responses to facilitate tumour killing. In order to mediate 
tumour rejection, an optimal combination of antigen, adjuvant and administration is 
required. However, conditions required for successful immunotherapy are poorly 
understood. Malignant cells frequently express antigens which can be recognised by the 
host immune system, but we know this response is often ineffective. Many tumour 
antigens have been identified and are capable of inducing a cytotoxic response. P53, Her2 
and MUC-1 are examples in breast cancer. In addition, many breast cancers express 
tumour-associated antigens which are potential therapeutic targets.
Dendritic cells are the most potent antigen presenting cells; they play a role in initiating 
anti-tumour immune responses. Qi et al (2000) showed that tumour antigens may be 
presented either by class II-positive tumour cells or by specialised antigen-presenting 44
cells attracted to the tumour site. As discussed previously, high densities of tumour 
infiltrating dendritic cells (TIDC) are associated with a favourable prognosis in some 
tumour types (Wright-Browne et al 1997). 
P53 is a transcription factor that regulates diverse genes involved in DNA repair and 
apoptosis (Zhao et al 2000). It is over-expressed in 57% of breast cancers and over-
expression is associated with a poor prognosis. Immunity to P53 peptides has been 
observed in breast cancer and P53 has been suggested as a target for immunotherapy.
MUC1, an antigen significantly up regulated in breast cancer, is also a focus of ongoing 
research. In a rat study, 60-80% of animals immunised with vaccinia virus–MUC1 
survived challenge with MUC1+ tumour cells (Hareuveni et al 1990). Murine models of 
breast cancer and in vitro systems have also provided insights for the study of breast 
cancer in humans. One successful approach in these murine tumours involved cytokine 
gene transfection of mammary cancer cells (Lebowski et al 1997). Although the antigens 
are not known, these genetically modified tumour cells invoke a dense lymphocytic 
infiltrate and in some cases the subjects were then resistant to further challenge with the 
parent tumour-cell line (Cavallo et al 1992). 
1.7.3 Vaccines45
Cancer vaccines aim to stimulate anti-tumor immune responses mediated by 
immunological effector cells such as CD4+ and CD8+ T lymphocytes and NK cells. 
Vaccination strategies used over the past years to immunize breast cancer patients (Ko et 
al 2003) have included use of irradiated or transfected tumour cells, dendritic cells pulsed 
with tumour cell lysate or peptides, and dendritic cells transfected to express tumour 
antigens. All of these clinical trials have been phase I or phase II. There were many 
limitations on these studies and their main significance has been to demonstrate that 
vaccines can activate antigen-specific cellular and humoral immune responses, which 
could potentially impact positively on outcome (Jager et al 2005).
In summary, immune responses have the potential to influence outcome in breast cancer. 
With the development of Herceptin, some progress has been made towards the goal of 
manipulating immune responses for therapeutic effect. However, if immune mechanisms 
are to be harnessed effectively for breast cancer treatment, better understanding of the 
contributions of B and T cell mediated processes, and the role of other inflammatory cell 
types, is required in breast cancer. 
1.8 Summary & Hypothesis46
A problem in many studies of the immune response in cancer is the use of qualitative or 
at best semi-quantitative measures of, for instance, density of tumour-infiltrating 
lymphocyte and other inflammatory cell populations. We wanted to attempt to quantify 
intra-tumoral immune responses in a group of breast cancer patients in a way that would 
improve the likelihood of obtaining meaningful results, and to investigate relationships 
between such measurements and clinical outcome. The experimental design chosen was a 
retrospective case – control study, which was felt to be the most effective way to control 
for known prognostically significant factors including grade, stage and steroid receptor 
status.
A major objective, therefore, was to develop an efficient method for quantifying the 
densities of the various immune cells contributing to the intra-tumoral immune response. 
To succeed in this objective would pave the way for further research on the contribution 
of different populations of infiltrating inflammatory cells in breast cancer, as identified by 
their distinctive immuno-phenotypes. Since breast cancer treatment is now standardised 
in the UK, and has been for about the last ten to fifteen years, we were able to take a 
group of patients in whom management had been planned according to standardised 
protocols in a uniform regional framework, and match 'cases' (women with breast cancer 
in whom metastatic relapse of breast cancer did occur) with 'controls' (women with breast 
cancer in whom metastatic relapse of breast cancer did not occur in the follow up period). 
Matching was to be based on several known, classical prognostic factors. 47
The hypothesis to be tested was that metastatic relapse would be less likely in women 
with breast cancers in which a significant immune infiltrate was present than in women 
with cancers in there was no significant immune-cell infiltrate. 48
Chapter 2: Quantifying Tumour-Infiltrating Lymphocyte subsets on 
 
                                Immuno-histochemistry (IHC)
2.1 Tumour Infiltrating Lymphocytes and Imunohistochemistry  
Breast cancers evolve over varying periods of time from intraepithelial neoplasia 
to distant metastases. We know that it is likely that TILS can influence this process,
through the mechanisms discussed in chapter 1 including cytotoxic T cells and 
ADCC. As metastatic progression is responsible for most cancer deaths, 
immunological killing of cancer cells shed into the blood or lymph could be 
important. The extent to which such mechanisms do actually control growth and 
dissemination of spontaneous human cancer remains unclear, but is the object of 
intense research, in diverse tumours including breast cancer(Liyanage et al 2002 , 
Hussein & Hassan 2006), melanoma (Hussein et al 2006) and others (Mufson 
2006, Willimsky 2005).
It is plausible that not only the intensity, but also the composition of the host 
response, in the form of an inflammatory infiltrate, could indicate the potential of 
immune surveillance to prevent progression to metastatic cancer.
In order to test this hypothesis we must measure the tumour-infiltrating lymphocyte 
populations. An efficient method for doing this that is not prohibitively laborious is 
essential. In doing this we also wanted to use a quantitative method rather than the 49
widely used  qualitative and semi-quantitative methods, which are poorly
reproducible. Hussein and Hassan in 2006 performed this manually, but in an 
endeavour to expedite the process, and to make it more efficient, we sought to design
an automated method which could be easily employed in studies, even with large
numbers of cases.
2.2 Cell types in Breast Cancer
In developing a method to facilitate quantification of the individual TIL types in breast 
cancer, we elected to quantify those cells types that others have shown to be present
frequently, although in varying quantities, in breast cancers.
T cells display extensive diversity of phenotype, function and distribution. Many studies 
have confirmed the heterogeneity of TILs in breast tumours(Leong et al 2005,
Georgiannos et al 2003).Several authors have found a predominance of CD4+ T cells in 
breast carcinomas(Marrogi et al 1997,Wong et al 1998).Others have however found that 
CD8+ T cells were present in greater numbers (Leong et al 2005).
Georgiannos et al (2003), in a study of 60 breast carcinomas, showed that CD3+ T cells 
were present in all of the tumours, in addition to CD4+ and CD8+ T cells.
Although there has been less in interest in quantification of the B cell component of the
immune cell infiltrate, B cells are often present in large numbers (Coronella et al 
2001) and CD20+ B cells have been found in breast carcinomas (Baxevanis et al 
1994). CD35 is found inter alia on follicular dendritic cells and is of interest as a potential 50
marker of ectopic germinal-centre like structures in neoplasia, predominantly on B 
lymphocytes. We elected to examine for CD 3+, 4+ and 8+ T cells and CD20+ B cells 
and 35+ cells, in this pilot study of our quantification method, as a precursor to future 
quantification in a larger study group.
2.3 Cell Quantification
The best counting method for a particular study depends on many variables including the 
level of accuracy and precision required, the nature of the objects to be counted and the 
available equipment and labour. There is no single described quantitative method that is
absolutely reliable and without bias (Guillery and August 2002). However making a 
quantitative assessment, even with some weaknesses, should be superior to a purely 
qualitative analysis, which the majority of studies to date,  examining TIL’s in breast 
cancer, have been(Pupa et al 1996,Georgiannos et al 2003).
In this particular study we wished to quantify individual cells. As cells are discrete, 
countable entities then an obvious unit of  measurement would be cells per mm3. 
However, this measurement requires 3D stereological tools such as the ‘optical dissector’
or ‘unbiased brick’ which may not be practicable for a large project and may indeed have
their own biases (Guillery and August 2002, Von Bartheld 2002).
As histological sections are quasi-two dimensional, a more accessible 
measure might be cells per mm2. Other possibilities include the volume fraction VV 
occupied by the immune cells, which, by the principle of Delesse (Royet, 1991), 51
could be estimated from the area fraction Aa of an infinitesimally thin section 
(approximated in reality by a histological section of conventional thickness).
Point counting estimates the area fraction and also therefore, the volume fraction, but 
if the volume fraction is small, the number of points which must be counted to
estimate it with a specified degree of precision is relatively large. A subjective 
element may also influence the decision as to whether a sampling point falls on the
object to be measured.
Binary thresholding of a digital image closely resembles ‘point counting’. Every pixel is
treated as a sampling point, and its colour properties determine whether it is to be
counted. Theoretically this seems straightforward, however, determining the 
appropriate threshold is not. For an immuno-peroxidase signal visualised with
diamino-benzidine and counterstained with haematoxylin, the problem is deciding
which pixels are ‘brown’ enough to represent signal to be counted  and which are 
either blue(counterstained nuclei) or unstained background.
A variety of approaches have been proposed, from simple thresholding of colour 
channels to complex image deconvolutions (Brey et al., 2003, Matkowskyj et al.,
2000 & Ruifrok and Johnston, 2001).
The approach we adopted was based on the idea that relevant pixels resembling
each other in colour, would therefore be co-located in an appropriate 3D colour
space (Poynton, 1995). In 24-bit RGB colour space 3 separate 8-bit (one byte)
numbers plotted on mutually perpendicular red, green and blue colour axes define a52
colour cube composed of 256   256   256 individual elements specified by each 
possible RGB number triple. In Lab colour space, luminance (L) is plotted against
mutually perpendicular chromaticity axes (a= green/red, b= yellow/blue). Proximity 
of points within a colour space designed to be perceptually uniform (Sangwine ,1998)
such as Lab colour space implies similarity of colour, and it appeared therefore that 
this proximity could be used to identify pixels representing the signal to be counted.
We also wanted to use readily available software, so Adobe photo-shop 7 tools were 
 employed.
2.4 Materials and Methods
2.4.1 Cases and Immunostaining
Sixteen invasive breast carcinomas of no special histological type were chosen at 
random from archives at Glasgow Royal Infirmary. For each case four micron 
sections of one representative block were immunostained as a single batch using a 
standard automated immunoperoxidase methodology and DAKO primary antibodies
against CD3, CD4, CD8, CD20 and CD35. For each immunostained slide ten
consecutive adjacent digital images of fields located at the infiltrative edge of the
carcinoma were acquired, starting at a random point, using a Fuji HC300Z digital
camera and a Nikon Eclipse E600 microscope with a x40 apochromatic objective, and
saved as uncompressed 24-bit RGB TIFF files. Field size (measured by stage
graticule) was 218°—170 microns=0.03706 mm2 =1/26.98 mm2  1/27 mm2, so cell
counts multiplied by 27 equal cell counts per mm2.53
2.4.2 Measuring the immunostaining signal
Adobe Photoshop (version 7) allows the colour of any individual pixel to be sampled
and set as the ‘foreground’ colour. The ‘Select/Colour Range’ tools allow all pixels in
the image having a colour similar to the foreground colour to be selected, which can
then be counted using the ‘Histogram’ tool. How closely colours in the image must
resemble the foreground colour is determined by setting a property known as
‘fuzziness’: a low value ensures that only pixels closely similar in colour will be
selected, while a higher value broadens the selected colour range, making it possible
to count the number of image pixels of a particular colour or colour range, narrowly
or broadly defined. Even if the open image file is in RGB mode, the Photoshop
‘Colour Range’ tool operates in Lab colour space. This can be demonstrated using the
‘LabMeter’ colour measurement software tool, available as a free download
(www.curvemeister.com). This provides a square image representing all values on the
green–red (a) and yellow–blue (b) chromaticity axes of Lab colour space (i.e. the a,b
colour plane), at a user-specified luminance value. Setting the foreground colour in
Photoshop to RGB 160, 67, 23 (Lab 41, 38, 44) and ‘fuzziness’=100, the ‘Select/Colour
Range’ command chooses a square portion of the Lab Meter image for which a=38±15
and b=44±15, inclusive. Varying the luminance (L value) of the test image or a
gradient image showed a slightly wider selection range on the luminance axis, with
L=41±19 inclusive being chosen. Lab 41, 38, 44 corresponded to a brown equivalent to
DAB staining of moderate intensity in our sections. Using fuzziness=100 includes54
weaker and stronger staining in the selected area. This value and range were chosen
to select approximately 90% of the area of the section in which the DAB signal could 
be identified visually. One hundred percent selection was not sought, to avoid
identifying areas of the section lacking specific staining. Figure 2.1 illustrates an
example of pixel selection in Photoshop with these parameters for an image of a
immunostained section containing many labeled cells, and one containing none. In all          
cases there was visual control of the selected area. It is also instructive to examine a
3D histogram of the pixel distributions of these images in Lab colour space 
(Figure 2.2). 
The stained section includes pixels corresponding to the DAB signal while the image
without labeled cells shows pixels corresponding to the background and nuclei only.
In essence, we are counting a representative subset of these pixels.55
Figure 2.1 : A: Immunoperoxidase staining shows many CD3+tumour-infiltrating
 lymphocytes in this breast carcinoma. 
B: outlined areas selected in Photoshop using ‘Select/Colour Range’ as described in
materials and methods. C and D: No CD35+cells are present in this field (C), and no
pixels are selected by Photoshop (D).56
Figure 2.2 : These images are 3D histograms of those seen in figure 2.1. 
On the left is CD3 and on the right is CD35. The difference in the colour distribution of 
coloured pixels between the two images as a consequence of the numerous CD3+cells 
and the absence of CD35+cells is obvious. These 3D histograms were generated using the
‘3D Color Inspector/Color Histogram’ plug-in [Kai Uwe Barthel] for the public-
domain image processing software Image (available at: http://rsb.info.nih.gov/ij/). 
Luminance is on the vertical axis and the chromaticity axes a and b are indicated on 
the base of the Lab colour cube.
2.4.3. Associating the measured signal with cell counts
The next step was to examine the relationship between the number of cells present in 
an image and signal strength measured by the number of pixels falling into a
particular Lab colour range. A total of 16 cases°—5 antibodies°—10 images=800 
images were collected on the same microscope, camera, and light setting, of slides57
stained in a single batch on an automated staining machine. These precautions were
observed to maximize consistency of analysis without extraordinary measures. CD35
positive cells were present in significant numbers in very few of these images,
and images of CD35 staining were excluded from subsequent analysis.
Each image was opened in Adobe Photoshop 7 with foreground colour set to R=160,
 G=67, B=23 and ‘fuzziness’ set to 100. The ‘Select/Colour Range’ tool was used to 
select the labeled pixels; these are highlighted on screen so that labeled cells can be 
identified. The number of selected pixels was recorded from the Image/Histogram
dialogue. The file was then closed and the process repeated file by file until all files
had been processed. If the number of labeled cells in an image was not too great, all
were counted to calibrate for that particular image the relationship (labeled pixels per
cell) between total signal and cell number. If there were too many cells to be counted
easily, the ‘Rectangular Marquee’ or ‘Lasso’ tools were used to define a representative
sub-region of the image within which all labeled cells could be counted and within 
which colour selection and pixel counting allowed a calibration (labeled pixels per 
cell) value to be calculated for that particular image. A complete field or field subset
cell count with the corresponding pixel count was made for every image. To be
certain that labeled cells were neither missed nor counted twice, the Eraser tool was
used to place a spot of colour on each labeled cell as it was counted. This was
quick and efficient.
The expectation was that the number of labeled pixels, for a particular combination of 
case and antibody, would be proportional to the number of cells present in a58
field; and that once the system had been calibrated, it would not be necessary to count 
individual cells, but only the pixels using the semi-automated methodology
described above. Particular interest was attached to variations in calibration from field
to field, case to case and antibody to antibody. Batch-to-batch variation was not
addressed, because if case-to-case variation in the relationship between pixel counts 
and cell number is significant, then calibration will have to be undertaken in every
case, which will control for batch-to-batch variation also.
For any individual field i the data available are the number, Pi, of labeled pixels in
the whole image; the number, pi, of labeled pixels and the number, ci, of cells present
in the calibration area. 
The estimated number of cells in a field is Ci=Pi / ( pi / ci); 
in fields containing few enough cells to count them all, the formula is Ci=Pi / (Pi / Ci), 
which cancels to Ci=Ci, as expected. 
The best estimate of the number of cells,  Ci, in all 10 fields is:
  CI = P1 (p1/ c1 ) + …. Pi  (pi / ci ) + …. + P10 (p10 / c10 )
and from this figure an estimate of the average calibration factor, F10, weighted in 
proportion to the number of cells present in individual fields can be derived as
F10 =   Pi /   Ci
We expected that it would be necessary to calibrate each case and antibody
combination individually, on account of differences in fixation and processing field
between cases, and differing epitope robustness and antibody binding affinity. We 59
wondered ,however, whether calibration for every field was necessary, given that all ten
fields were adjacent to each other on the same section, and had been exposed to identical
handling, dissection, fixation, processing, storage and staining. We sought, therefore, to 
find the minimum number of fields which would have to be calibrated by cell counting to
allow an acceptable estimate of the number of cells present, in comparison with the 
number of cells estimated by calibrating every field.
Our data allow us to examine variations in the pixels/cell calibration factor on a field-
to field, case-by case and antibody-by antibody basis. Plotting all individual pi / ci 
measurements against Pi for all cases, antibodies and fields (CD3, CD4, CD8, CD20)
allows us to see relationships between the calibration factors and the total labeling 
(Figure 2.3).
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Figure 2.3 : Scatter plot of calibration factors pi/ci for all evaluable fields.
The calibration factor is plotted on the x axis against the number of labeled pixels Pi 
in the image which yielded that calibration factor for CD3 (triangle), CD4 (diamond), 
CD8 (grey diamond) and CD20 (circle)
Where few labeled pixels are present in a field, there is wide variation in the
calibration, but the estimates of the calibration factor derived from fields in which 
more labeled pixels are present fall within a narrower range. It appeared appropriate
therefore to base the calibration on the fields containing the largest number of labeled
pixels, to reduce noise associated with smaller cell and pixel counts.
Accordingly, three different estimates were made for each case/antibody combination: 
the calibration factor (over all 10 fields) was calculated as described above (F10); and 
estimated using calibration factors calculated from the field m containing the greatest
number of labeled pixels as F1=( pm / cm); from the sum of that field and the field 
m  with the next largest number of labeled pixels as F2=( pm +pm ) / (cm+ cm ) and 
from the sum of the three fields with the largest, second and third largest number of 
pixels as F3=( pm+pm + pm  /(cm+cm  +cm ).
In expressing actual cell counts, the number of cells per field has been multiplied by 
27 to give the results in cells per mm2.61
2.5. Results
2.5.1 Comparison of F10 against F1, F2 and F3
A scatter plot (Figure 2.4) shows a greater degree of scatter for F1 against F10 than
for F2 or F3 against F10, as might have been expected. We can look more closely at 
the degree of agreement (following Bland and Altman1986) by computing
100(F1 F10) / 0.5(F1+F10), 100 (F2 F10) / 0.5(F2+F10) and 100(F3 F10) / 
0.5(F3+F10) to express the degree of agreement between the different calibration
factors as a percentage of their means. The mean difference and its standard deviation
are: F1 v F10, 8.3% (17.4%); F2 v F10, 5.3% (10.2%) and F3 v F10, 4.4% (7.8%).
Clearly, F3 agrees best with F10, but F2 is nearly as good and is less
work to derive, requiring only two calibration measurements. 62
Figure 2.4: Scatter plot of calibration factors (pixels per cell) derived from all 
evaluable fields. The calibration factor F10 is plotted on the x axis against the three
calibration factors derived from available measurements for the single field with the
most labeled pixels (F1; small  ), the two fields with the most and second most
labeled pixels (F2;  ), and the three fields with the three most labeled pixels (F3;
larger grey  ). One-field calibration shows considerably more scatter than two- or
three-field calibration
The differences are normally distributed (judged by normal probability plots and
Shapiro–Wilk W test), so these figures tell us that we can be 95% confident that a cell
count using F1 will not be more than 42.5% greater and not more than 25.9% less than a 
cell count derived using F10. The 95% confidence limits for F2 are +25.3% and  14.7%
and for F3 are +19.6% and  10.9%. For many purposes these will offer adequate 63
accuracy and precision.
2.5.2. Differences in calibration between antibodies and between cases
This section looks at whether it is necessary to calibrate cell counting for different 
cases or different antibodies. Figure 2.5 plots the raw calibration data for CD3, CD4,
CD8 and CD20. 64
Figure 2.5 Scatter plot of calibration factors (pixels per cell) derived from all 
evaluable fields arranged by case and by antibody. Each vertical column of data
points represents one case from 1 to 16 and the order of cases is the same for each
antibody. Calibration factors are comparable for CD3 and CD8; those for CD4 tend to
be lower and for CD 20, higher.
Another way of looking at this is to take mean F10 values for all cases for each
antibody. For CD3 the mean F10 is 770 pixels/cell±SEM 61; for CD4 it is 603±53; for
CD8 it is 896±67; and for CD20,1161±103. Were one to take the mean of these
values (857.5 pixels/cell) to represent them all, the number of CD20+B cells and
CD8+T cells would be systematically overestimated by 35% and 4.5% and CD3 and65
CD4+T cells would be underestimated by 10.2% and 29.3%. These represent non-
trivial biases which for many purposes would not be acceptable.
Figure 2.6 looks at case to case variation. It plots normalized factors F10 for CD3, 
CD4, CD8 and CD20 and shows that that generally the calibration factors F10 lie in
a range between about 75% and 140% of the average for the series. One case is
clearly an outlier and may have been subjected to unusually lengthy fixation. Again, 
the differences in the relationship between the pixel counts and the cell counts which 
they imply suggest that this variation must be taken into account.66
Figure 2.6 : Scatter plot of calibration factors F10 for CD3, CD4, CD8 and CD20: 
CD3 (triangle), CD4 (diamond), CD8 (grey diamond) and CD20 (circle). Data are 
normalised against mean F10 and ranked by mean normalized F10 value. This plot
indicates that for the most part calibration factors F10 lie in a range between about
75% and 140% of the average. The first case is clearly an outlier and may have been
subjected to unusually lengthy fixation. ‘+’ indicates mean normalized F10 values
Finally, it is worth taking a preliminary look at the range of densities of different TIL 
populations in breast cancer. This gives some indication of the kind of precision
which must be achieved to detect biologically significant differences; if the range is
very wide then greater precision may not be required in comparison to the situation
which would obtain if the range of observed densities was small.
Figure 2.7 and Table 1 present this data in units of cells per mm2.67
Figure 2.7 : Scatter plot of cell counts for CD3, CD4, CD8 and CD20: CD3 (triangle), 
CD4 (diamond), CD8 (grey diamond) and CD20 (circle). There is a wide range of 
values for each lymphocyte sub-population68
Table 2.1 :
The range of TIL densities is very wide; there are major differences between different 
cases in the intensity of the TIL response evoked, in keeping with subjective impressions 
of the situation.
 
CD3 CD4 CD8 CD20
Mean 12,900 6016 7010 4750
SD 15,700 5570 6600 5850
Median 6280 5160 4280 1860
Total Range 490–59,700 54–20,000 270–22,800 0–16,092
IQ range 3969–14,158 1958–8330 2997–9126 54–10,031
This is a pre-condition for significant differences in tumour behaviour to be related to 
TIL density, and makes the task of analysis easier. IQ range = interquartile range.
2.6. Discussion69
Immunostaining pixel counts made using a widely available tool (Adobe Photoshop) 
can be converted into cell counts per mm2 for tumour infiltrating lymphocyte subtypes. 
Likely errors associated with this conversion are moderate in comparison with the 
range of TIL densities in breast carcinomas in this preliminary study, although one
must not be unrealistic about the accuracy likely to be achieved. While heterogeneity
of staining between samples is reasonably well compensated for by the calibration 
process, compensation for heterogeneity within samples will depend on the number of 
fields in which calibration is carried out.
A purpose of this study was to develop a methodology employable in larger-scale
studies. Many studies published in the pathology literature are statistically
underpowered. Our ongoing case/control study of outcomes in breast cancer is 
designed to examine 111 breast cancer patients (‘cases’) in which metastatic relapse 
occurred and 222 cancer patients (‘controls’) without relapse.
Carcinomas are matched for size, grade, estrogen-receptor and lymph node status, and 
the women are matched by age as a surrogate for menopausal status.
Examining a core set of TIL subtypes (CD3, CD4, CD8 and CD20) will require
measurement of 333°—4°—10=13,320 digital images. High-throughput approaches
to the analysis of 40 gigabytes of image data are required.
Manual processing of all images in Photoshop is a non-starter. We view this enabling,
preliminary study as a stepping stone to a more streamlined approach.
Calibration of the conversion from pixel counts to cell counts is required for each 
case/antibody combination.70
For a set of histological sections immunostained as a batch on automated staining 
equipment, identical colour selection parameters can be used on all sections in that 
batch; visual inspection showed satisfactory selection of areas identified visually as
immunostained with DAB from field to field, case to case and antibody to antibody, 
all in the same batch.
We studied 640 images in this pilot study. Total labeled pixel counts were made
manually for all these images. We have made good progress towards automation of
this step and a program has been written, by Dr Alison Gray, University of Strathclyde,
for batch processing of image files. 
This program is written in C, for which compilers are readily available for different
computer platforms (Windows, Apple, Unix/Linux etc.), and calls the public domain
image processing software ‘ImageMagick’ (http://www.imagemagick.org) to convert 
different image file types into a format suitable for image arithmetic to count the 
number of image pixels which meet the user-specified criteria (i.e. L,a,b ranges) for 
the signal.
These criteria may be established within Photoshop. Photoshop does not offer a tool 
revealing Lab ranges implied by specific ‘Colour Range’ and ‘Fuzziness’ settings; 
indeed there is no published algorithm detailing precisely how Photoshop performs 
the image arithmetic behind these tools. However, these parameters can be derived
using the LabMeter tool (free from www.Curvemeister.com) to measure the a,b range
and a very useful array of 100 small images of the Lab colours with luminance vales 71
from 1 to 100, created by Gernot Hoffman (see www.fho\-emden.de/~hoffmann/
hungams17042004.pdf).
Even in its present form the method could be used for studies in a small to medium
scale. We do not think it will be possible to avoid the need to calibrate images
manually, although ‘histogram specification’ may be worth exploring to see how it 
performs in this context.
This transforms each colour plane in a new image to have the same colour histogram 
as a reference image. There are no a priori reasons to think the method will not work 
with cytoplasmic or nuclear antigens, although these were not included in our studies. 
Validation studies would be prudent before applying the method to such antigens.
Although we did not address this issue, the number of fields which need to be 
measured before a stable estimate of TIL density is obtained could be established
from running means.
Another issue we did not address is that of quantifying TILs in different 
compartments within a carcinoma, e.g. stromal, epithelial, or perivascular (Hussein 
and Hassan, 2006). Our method could be adapted to this by using the Photoshop 
‘Lassoo’ tool to define separate compartments within which TILs are to be quantified.
For some purposes, calibration based on a single image from a set may define a 
conversion factor with adequate precision in a particular application. For the 
application we have described two fields appear sufficient. This represents an 80% 
reduction in the labour of counting, compared to 10-field calibration. This
brings the method within the range of what is practicable and should facilitate the use of 72
objective histological cell counting in clinical and experimental tumour immunology.
Chapter 3: Quantification of Tumour-Infiltrating lymphocytes on H& E stained 
tumour sections: A Case-Control Study 
3.1 Study Design
3.1.1 Background to Study Design
As stated in the hypothesis, our aim was to examine the lymphocytic infiltrate in a
 
cohort of breast cancers and examine the association between this infiltrate and 
prognosis . In designing a prognostic study it is essential to control for already
recognised prognostic factors. A defined minimum length of follow up of is required, 
due to the variable time to progression in breast cancer, which may be prolonged.
Prognosis in operable breast cancer is influenced by a number of clinical and
pathological factors. A prognostic factor is any measurement available at the time of 
surgery that predicts  disease-free or overall survival in the absence of systemic 
adjuvant therapy. In contrast, a predictive factor is any measurement allowing a 
degree of prediction of response to a given therapy.
Some factors, such as hormone receptor expression and HER2/neu over expression, 
are both prognostic and predictive73
3.1.2 Nottingham Prognostic Index (NPI)
Many prognostic factors in breast cancer have been described but only some of
these retain independent significance in multivariate analysis, for example the numbers of 
nodes involved by tumour.
The importance and utility of such independently significant factors is recognised in 
the well established and widely used Nottingham Prognostic Index (Haybittle et al 
1982). This is used to predict survival in operable breast cancer and was first 
described in 1982. 
NPI is compiled from the size, grade and lymph node status of the primary 
tumour. It has both intra- and inter- centre validation (Todd et al 1987, Sundquist et al
2002). The ability of this index to separate patients into groups with significantly 
differing probable survival, to achieve wide separation between these groups and the 
fact that its applicable to all operable breast cancers, be they symptomatic or screened 
(Lawrence et al 2003) means it is a satisfactory discriminatory tool when predicting 
survival.
NPI is calculated in the following manner:
NPI = 0.2   tumour size (cm) + lymph node stage + grade (1-3) and prognosis and 5
year survival rates are detailed below
NPI Score Prognosis 5 year 
survival
2.0-2.4 Excellent 93%
2.4-3.4 Good 85%
3.4-5.4 Moderate 70%
> 5.4 Poor 50%74
                       Table 3.1: NPI & Survival
3.1.3 Nodes
It has been known for many years that lymph node involvement by metastasis is the 
single most important prognostic factor, following surgery for primary breast 
cancer (Smith et al, 1977), and there is a direct relationship between the number of 
involved axillary nodes and the risk of distant recurrence ( Saez et al 1989).
Lymph node involvement 
contributes scores of 1-3 to 
the  NPI as shown below:
           Table 3.2: Nodal Groups for NPI
3.1.4 Carcinoma Size 
The size of a carcinoma does correlate with the number of involved axillary  
lymph nodes, but is also an independent prognostic factor in breast cancer.
The larger the tumour, the greater the risk of developing distant metastases 
Score Number of nodes involved
1 0 Nodes
2 1-3 Nodes
3   4 Nodes75
(Carter et al 1989). Metastases from larger cancers, do occur more quickly but the
increased risk does persist over long term follow up (Rosen et al 1993).
In those cancer patients who have no axillary nodal involvement, the size of the
tumour becomes a proportionately more important prognostic factor. Tumour size 
influences decisions regarding adjuvant therapy and in general the larger the tumour 
the more likely one is going to need some form of such treatment.
3.1.5 Carcinoma Grade
Pathologic characteristics of a carcinoma, including its grade and histological type, 
have prognostic significance. Certain subtypes such as tubular, mucinous and possibly 
medullary have a more favourable prognosis (Carstens et al 1985).
Multiple grading systems have been proposed, with the most widely accepted being 
the Scarff-Bloom-Richardson (SBR) classification (Bloom et al 1957), which became 
the basis of the Nottingham grade (Elston & Ellis 1991). This refinement of the SBR 
grade addresses issues of reproducibility by defining appropriate grading criteria.
Tumour grade particularly influences treatment decisions for lymph node-negative 
patients and those with borderline tumour sizes. 
 NPI scores tumour grade in the following way:
Score Grade
1 Well differentiated
2 Moderately differentiated
3 Poorly differentiated
        Table 3.3: NPI; Tumour Grade76
3.1.6 Oestrogen receptor status
Oestrogen receptors (ER) are nuclear steroid hormone receptors. Their activation is 
linked with the regulation of certain genes, particularly those controlling cell growth.
Oestrogen receptor (ER) assays in breast cancer has been a routine test for 
approximately 30 years. Early biochemical assays have been superseded by more 
reliable immuno-histochemical assays. ER status predicts response to hormonal 
treatment (Jensen et al 1985), and in particular it is used to predict the clinical  
response to anti-oestrogen treatments, for example tamoxifen and more recently 
aromatase inhibitors. It was later recognised that determination of ER status could 
help in the prediction of overall  prognosis(Hahnel et al 1979). 
Several studies have demonstrated that the breast cancer specific survival of ER 
positive cancers is better than ER negative cancers (Hahnel et al 1979, Hahnel et al 
2004).
However the early survival benefit of ER positivity is not maintained over
time and  Hahnel et al (2004) found a trend towards increased mortality after
five years, with a tumour that is ER positive.
The combination of ER and PR status may further refine the prediction of77
the response to endocrine treatment. Overall, ER is perhaps best considered as a 
"predictive" rather than prognostic factor.
3.1.7 Age/Menopausal status
Age is an important predictor of response to both hormonal and chemotherapies, and 
has prognostic implications. In women under the age of 35 there is a greater incidence
of high grade tumours and an association with reduced survival (Nixon et al 1994).
Many studies evaluating the influence of age on outcome in breast cancer have been
small, with conflicting results (Fowble et al 1994 & Mueller et al 1978). Two
relatively large trials did, however, demonstrate a worse prognosis for patients
 younger than 35 years of age, even after adjustment for other prognostic factors 
(Nixon et al 1994 & Albain et al 1994). However, age is generally used as an adjunct
to other prognostic factors that are better validated such as tumour size, when
determining treatment and expected outcome.78
3.1.8 Follow up and Recurrence 
Breast cancer is a heterogeneous disease. Unlike for example, rectal cancer, 
which can be considered ‘cured’ if a patient is disease free five years after primary 
surgery (Moore et al 2005), breast cancer can recur up to fifteen and twenty years 
after initial diagnosis. 
Figure 3.1: Illustrates the probability of relapse free survival 
                 over a 20 year period (Retsky et al 2005)
In this cohort of patients, approximately 75% of all recurrences had occurred within 
five years. This indicates that a minimum follow up of five years allows for 
meaningful comment on disease free survival, whereas a shorter follow up period 
would not.79
Figure 3.2: Illustrates that while overall survival is increasing, mortality from breast 
cancer can still occur up to twenty years later. However, most recurrences still occur
within the first five years.
3.1.9 Patient Source
We selected our patients from the Greater Glasgow Health Board (GGHB) database.
This is a database established in 1995 with the intention of keeping a prospective
record of all patients diagnosed with breast cancer in the Greater Glasgow area. It 
records patient demographics in addition to clinical and pathological data, and 
subsequent treatments. The intention is that the database should be followed up over 
the long term to allow outcomes to be recorded. I participated in gathering a 
significant proportion of this data through case note review.
 Information regarding death, which was not recorded in case notes, was obtained from 
 the Scottish cancer death registry.
The GGHB database documents that between October 2005 and December 2000, 
3204 patients have been diagnosed with primary operable breast cancer.
Overall there were 684 deaths from this period, however only 392 were directly80
attributable to breast cancer.  The database does not have a record of overall numbers 
diagnosed with metastatic disease, however it is accepted that if one dies as a result of 
breast cancer one has to have distant metastatic disease. All of the cases used in this 
study had documented evidence of systemic metastases.
3.2 Ethics
Ethics approval was sought from the North Glasgow University Hospitals NHS Trust 
Ethics committee and was approved on 21ST June 2004.
Ethics Reference no: 04/S0705/7
3.3 Type of study  & Power Calculation
In order to investigate the influence of lymphocytic infiltration in breast cancer on 
patient survival, we decided to implement a case-control study .
It was felt that with access to such a large database that this was the method that 
would provide results of most significance. In particular, since so many 
different factors can influence the outcome in breast cancer , we felt that this would be 
the most appropriate way to control for these factors.
At the time of commencing the study, we had planned to include only those patients 
diagnosed between 1995 and 2000, assuming in 2005, that we would not have 
completed five year survival data beyond this. 
However we were subsequently able to extend the study period to include 
2001, as we had completed follow up data by the time of completion of the study.
The power calculation, was based on the number of patients diagnosed with
breast cancer between 1995 and 2000 (i.e. 3204 patients) and the probability that 
approximately 50% of them would have evidence of an inflammatory response (Billik 
et al 1989).With the aid of the statistics department at the University of Glasgow, it was 81
estimated that we would require 111 cases and 222 controls. It was calculated that these 
numbers would give the study a power of 80% to detect a two-fold relative risk of relapse 
between groups, with 95% confidence. This calculation was performed using the
statistical programme Epi-info version 6.
3.4 Patient Selection
3.4.1 Background
Having elected to perform this study as a case – control series we determined that our
cases would be those individuals who had developed distant metastatic disease .
In choosing our controls we felt it would be necessary to account for the 
aforementioned prognostic data. Therefore we matched our cases and controls based
on the following five characteristics :
1. Menopausal status – we chose 50 as the cut off for being assigned to either the pre- 
or postmenopausal groups as this is usual practice in the clinical setting when
determining adjuvant therapies.
2. Tumour size – categories were as per those used in NPI;
         -   < 2cm
         -   2-5cm 
         -   > 5cm
3. Tumour grade – as per NPI
4. Number of positive axillary lymph nodes - again as per NPI
5. Oestrogen receptor status – positive / negative
We did not control for treatment as this has been standardised to the extent that it is
reasonable to assume that patients with similar disease and patient characteristics
 would have had similar treatments.82
3.4.2 Inclusion Criteria 
A.  Cases
All those on the database who were diagnosed with primary breast cancer and who 
subsequently developed distant metastatic disease or whose death was attributable to
their breast cancer.
B. Controls
Two individuals were chosen to control for each case. Any individual on the database 
who matched a case, based on the previously mentioned five characteristics and
had at least five years of completed follow up.
3.4.3 Exclusion Criteria
A.  Cases
1) Any case who did not have surgery.
2) Any case for which two matched controls could not be identified.
3) Any case for which a haematoxylin and eosin stained tissue section could not be found.
B.  Controls
1) Those who did not have at least five full years of follow up
2) A patient who had developed distant metastases at any time during the follow up 
period was not included as a control and would automatically become a ‘case’.
3) Any individual whose death was attributable to their breast cancer.
4) Anyone who did not have surgery.
5) Anyone for whom a haematoxylin and eosin stained tissue section could not be 
found.
3.4.4 Final patient group
The study was carried out over the period 2005-2007. Therefore in order to ensure83
that our controls had a minimum five year follow up, we did not use patients who had
a primary diagnosis after 2001.
Between 1995 and 2000 the GGHB database has recorded a total of 3204 patients
diagnosed  with primary operable breast cancer. Of these, 392 died from breast 
cancer and  292 of another cause.
In total we had 127 cases for which we could identify two matched controls. There 
were obviously many more ‘cases’ on the database, however, we had some difficulty 
matching all of them with suitable controls. The majority of those that could not be 
matched were the largest tumours, i.e. those over 5cm and or the ones with large numbers
of positive lymph nodes. The reason for this, unsurprisingly, was that it was difficult to 
find patients in these categories who had not developed distant metastases.
However our final number in the study was reduced because haematoxylin and eosin
stained sections, from resected cancer specimens, could not be found for 57 patients.
This number includes both ‘cases’ and ‘controls’. 
Our final numbers for inclusion are:
A) 90 cases
B) 180 controls.
3.5 Materials and Methods for  counting on Haematoxylin & Eosin (H&E) 
      stained sections84
3.5.1   Background
Many previous studies of lymphocytes in breast cancer have used
semi-quantitative (Scholl et al 1996) or qualitative methods (Lee et al 2006).
We wished to use a strictly quantitative approach, which would however not be 
prohibitively laborious.
We therefore used a validated method, established by Going in 1994, to count the 
inflammatory cells. This method is based on 1) random sampling (Simpson et al 
1992) and 2) the unbiased counting rule (Gunderson 1978).
The usual approach to counting cells in a microscope is to use an eyepiece graticule in 
the form of a 10 x 10 square grid and to count all the cells in this area ,using the grid 
as a guide to avoid counting the same cells more than once. Going established that by 
counting cells in a random subset of small squares, for example 10, and then 
multiplying this number by 10 would give an unbiased estimate of the number of cells
in a grid of 100 small squares. By repeating the procedure over ten fields the degree 
of total error was reduced to an acceptable level, ± 5% of the fully counted total, and 
significantly the observer only needed to count 10% of all cells present.
3.5.2    Imaging the Sections for counting
Tumour infiltrating lymphocytes may be found within the stroma of the tumour but 85
also often at the edge of the tumour (Lee et al 1996).We counted the inflammatory 
cells on H+E stained sections of breast cancer in ten consecutive fields along the edge 
of the tumour. One reason for this choice was to avoid inflammatory responses to 
areas of necrosis.
Using a computerised camera microscope system (Fuji HC300Z digital camera and a 
Nikon Eclipse T600) at x40 Apo chromatic objective, a photograph was taken of 10 
consecutive fields starting wherever tumour edge was found closest to the top 
left hand corner of  each section. This random starting point was consistently used for 
each case. A total of ten images was taken for each of 366 cancers (a mixture of both 
cases and controls). However only 270 of these could be used in the final study as the 
remainder were either cases for which two control slides could not be found or vice 
versa.
The photographs were saved as uncompressed 24-bit RGB TIFF files, for counting at a 
later date. 
3.5.3   Counting the Inflammatory cells
We used Image J (http://rsbweb.nih.gov/ij/), an image processing tool kit, available in 
the public domain, to facilitate the counting of inflammatory cells on the images we 
photographed. 86
The ‘process’ application in Image J was used to superimpose one of four different 
pre-constructed counting grids, via the ‘AND’ mode, on each the ten images of the 
H&E stained section for each case.
Each counting grid had within it 10 highlighted rectangles (Figure 3.3).The same 
arrangement of rectangles was highlighted in grids (A-D), but rotated by 900 between 
A-D, B-C, C-D and D-A.
One of the four grids was selected at random for counting each case.
Using the unbiased counting rule (Gunderson 1978) inflammatory cells were only 
counted if they either fell within the highlighted squares on the grid or along the 
‘northern’ or ‘western’ border of these highlighted squares , as illustrated in figures
3.4. and 3.5 . As per Going’s counting method, the total number of cells over the 
counted 10 squares was then multiplied x 10 to give an estimate of the cell count for 
the whole image. . Field size (measured by stage graticule) was 218°—170
microns=0.03706 mm2 =1/26.98 mm2  1/27 mm2, so cell counts multiplied by 27 equal 
cell counts per mm2.
A record was kept of which grid was used with each case.
For the first twenty tumours imaged, cell counts were performed by two observers trained 
in the counting method. 
The counts were largely comparable.87
Figure  3.3 : Grid A
Figure 3.4 : Grid D8889
Figure 3.5: Example of Counting Grid superimposed on an image of a H&E stained 
                   breast cancer section. The cells to be counted are highlighted in                    
                   blue (Going, 2006)
Figure 3.5 illustrates the counting process. The large square is subdivided into 100 
small squares, 10 of which are picked out by their heavier border. Eleven cells
(marked with blue spots) to be counted are identified by the unbiased counting rule
using upper and left inclusion edges, giving an estimate of 11 x 10 = 110 cells in the
large square. Actual cell count is 124.90
Figure 3.6 : Illustration of the unbiased counting rule (Going 2006)
Figure 3.6 illustrates the unbiased counting rule. Consider the sampling square 
in the centre of this 3 x 3 array. Imagine two inclusion edges (green) above and to the
left and two exclusion edges (red) below and to the right of the sampling square. Cells 
to be included in the count (blue dots) touch or lie below or to the right of both
inclusion edges, but do not touch or lie below or to the right of either exclusion edge 
Excluded cells are identified with red dots. This rule is easy to apply in practice once 
learned. In expressing actual cell counts, the number of cells per field has been multiplied
by 27 to give the results in cells per mm2.91
3.5.4 Statistics Employed
Analyses were performed using a combination of Microsoft Excel for the descriptive data 
and programme R , a web based statistics package , for the analysis.
A combination of paired and unpaired t –tests were used
3.6 Results
3.6.1 Descriptive Statistics 
90 ‘Cases’ had cell counts calculated on H&E stained tumour sections.
                 Range: 0-1770
                 Median count:  583.8
This demonstrates the wide variation in counts between all the cases.
180 Controls had cell counts calculated on H&E stained tumour sections
                   Range:  0- 4790
                   Median Count:  627.8
Again a wide variation is seen in the range of cell counts for all 180 controls.92
Figures 3.7 and 3.8 are examples of ‘cases’ with a low IID (overall cell count for this 
‘case’ was 93 per Square mm) and a high IID ( 2241 per Square mm) respectively.
Figure 3.7:  ‘Case’ 432 
Figure 3.8: ‘Case’ 1257 (some of TILs circled in red)93
Figures 3.9 and 3.10 are examples of ‘controls’ with a low IID (overall cell count =108 
per Square mm) and a high IID ( 1426 per Square mm) respectively.
Figure 3.9: ‘Control’ 143794
Figure 3.10: ‘Control’ 542 (some of TILs circled in blue)
Menopausal Status
Overall , out of the 270 patients 183 of them were presumed to be post-menopausal, as 
determined by age >/= 50 . 87 of them were pre-menopausal. This is in keeping with 
the expected distribution of age given that the incidence of breast cancer increases
with age.
 Table 3.4: Distribution of patients according to menopausal status
Pre-menopausal   87    (32.2 %)
Post-menopausal 183    (67.7 %)
              
                             95
Size
The range of size was 4-60mm for the cases and 5 – 55mm for the controls. Overall 
the median size was 20mm.This is not unexpected. Since the introduction of breast 
cancer screening, more tumours are being diagnosed earlier and are therefore likely to 
be smaller (Hofvind et al 2008).
Tumour grade
As illustrated in table 3.3 the majority of the tumours were either grade 2 or 3. Only 12 
out of 270 patients had a grade 1 tumour. The median tumour grade was 2.
Table 3.5: Distribution of patients by tumour grade
Grade Total Number (%)
       1            12   (4.4 %)
       2          132  (48.9 %)
       3          126  (46.7 %)
Nodal Status
The range of positive i.e. tumour involved axillary lymph nodes was 
0-17 for the ‘Cases’  
0-19 for the controls
The median number of positive nodes was 1.96
Oestrogen Receptor Status
Table 3.6 shows the distribution of ER status amongst all tumours.
Table 3.6:
ER Positive      168  (62.2%)
ER Negative      102  (37.8%)
These figures are in concordance with the literature. Approximately 60% of those with 
breast cancer will have functioning oestrogen receptors.
3.6.2 Data Analysis
3.6.2.1 Data distribution and Transformation
For the initial analysis, data from all patients (n=270), i.e. both ‘case’ and controls, were
grouped together. This was done to analyse the data in the whole group, without regard to
pairing. We firstly wanted to establish if the inflammatory infiltrate densities (IID) were97
normally distributed, or not.
To do this a quantile-quantile plot (Q-Q plot) is used. It is clear from figure 3.11 that the
 
line is strongly curved indicating that the data is highly non-normal.
 
Figure 3.11 : Q-Q plot of untransformed Inflammatory Infiltrate Density
                     data (per mm2)
A histogram of the same data seen in figure 3.12 again confirms the data is strongly 
skewed, and non-normal.98
Figure 3.12: Histogram of IID per mm2
On the advice of Dr. J Paul, statistician at the University of Glasgow, we then went on to
‘transform’ the data into a form in which it was normally distributed. We looked at both 
square and cube root transformations, of which the latter was felt to be optimal. These
statistical transformations are perfectly legitimate because they are applied equally to all
of the data.
Figures 3.13 and 3.14 illustrate the Q-Q plots of the square root and cube root 99
transformed data respectively. 
Figure 3.13: Q-Q plot of the square root transformed IID data 
Figure 3.14: Q-Q plot of the cube root transformed IID data
Clearly the cube root transformation is most linear and represents the data in a normally 100
distributed manner. This was the transformation therefore chosen for statistical testing.
3.6.2.2 Comparison of IID between ‘Cases’ and Controls
The range of cell counts for both groups of patients were widely distributed. This is 
illustrated in the histograms in figures 3.15 and 3.16
Figure 3.15: Histogram – Range of cell counts for all ‘Cases’ n =90101
Figure 3.16: Histogram – Range of cell counts for all Controls n= 180
Next we examined the relationship between the IID and status of the patient as a case or a 
control. To do this parallel boxplots were constructed, figure 3.17
It would appear that there is no obvious difference in the distribution of the IID values
between ‘cases’ and controls.102
              Figure 3.17: Boxplot comparing IID per mm2 Cases (1) and Controls (2) 
We used a two sample t-test to compare the difference. Since this assumes normality of 
the data it was applied to the cube root transformed data. It also assumes the variances of 
the data are the same in the two groups.
The result was non-significant, p = 0.2319, 95% confidence interval.
Whilst this is a useful test it does not take into account that our data was made up of 
‘cases’ paired with two controls.
In order to compare ‘cases’ directly with ‘controls’ the mean value of the two cell counts 
permm2 , for each of the two controls was calculated. It was then possible to perform a 
paired t-test  which did show a significant difference between the two groups,
p = 0.04478, 95% confidence interval.103
This demonstrated that the IID is significantly greater in the controls than in the ‘cases’.
Although the unpaired data did not allow this conclusion, it was not the most appropriate 
analysis.
However, the average difference in IID between ‘cases’ and controls is small. A boxplot,
seen in figure 3.18 of the untransformed data illustrates this.
       Figure 3.18: Boxplot of the average difference between ‘cases’ and controls
The average difference, although statistically significant, is much less than the ‘noise’ in
 an individual case and therefore would have no prognostic value in an individual case.104
.3 Association between IID and Prognostic Factors
3.6.2.3.1 IID and Menopausal Status
Table 3.7 illustrates the IID in patients when classified according to menopausal status.
The maximum cell count 7424.5 for the post-menopausal group is much 
greater than that of the pre-menopausal patients, 4557. There is, however no significant 
difference between mean cell count per mm 2 in the two groups,(p = 0.66).
Table 3.7 :Differences in cell count data between pre- and post-menopausal groups
Postmenopausal Count mm2  Premenopausal Count mm2 
Mean 865Mean 929.2
Standard Error 71.8Standard Error 93.9
Median 567Median 798.2
Range 7424.5Range 4557
Minimum 0Minimum 15.5
Maximum 7424.5Maximum 4572.5
3.6.2.3.2 IID and Tumour Size
Table 3.8: Cell count data for all tumours in relation to size
Size <20mm  Count mm2 Size 20-50mm Count mm2  Size >50mm Count mm2 
Mean 828Mean 872.1Mean 735.2
Standard Error 70.2Standard Error 65Standard Error 267.7105
Median 573.5Median 604.5Median 592.7
Range 6107Range 7424.5Range 1491.1
Minimum 0Minimum 0Minimum 46.5
Maximum 6107Maximum 7424.5Maximum 1537.6
The degree of inflammatory infiltration does not appear to be related to tumour size based 
on this data. When put into groups based on tumour size being   20mm or > 20mm there 
was no difference in the mean IID, P = 0.1695
3.6.2.3.3 IID and Tumour Grade
Table 3.9 : Illustrates the IID data for tumours according to grade
Grade 1 Count mm 2 Grade 2 Count mm 2 Grade 3 Count mm 2 
Mean 1068Mean 712Mean 1049.9
Standard Error 469.6Standard Error 66.2Standard Error 89.6
Median 570.2Median 433Median 879.5
Range 5998.5Range 5130.5Range 7424.5
Minimum 108.5Minimum 0Minimum 0
Maximum 6107Maximum 5130.5Maximum 7424.5
 The difference between the mean IID for grade 1 and the means of the other two were 
not significant. However there was a significant difference between the grade 2 and grade 
3 tumours (p = 0.002). The grade two tumours had a significantly lower IID. We 
then classified the tumours into two groups, low grade (includes grades 1+2) and high 
grade (3).Again the difference was highly significant, p = 0.00045. The high grade 106
tumours had a significantly denser IID. 
3.6.2.3.4 IID and Nodal Status 
Table 3.10 : Cell counts based on nodal status
0 Nodes 
Positive 
(Group1) Count mm 2
1-3 Nodes 
Positive 
(Group 2) Count mm 2
  4 Nodes
Positive
(Group 3) Count mm 2 
Mean 929.6Mean 916.7Mean 712.3
Standard Error 88.6Standard Error 100.9Standard Error 88.3
Median 720.7Median 570.2Median 565.7
Range 6107Range 7424.5Range 2241
Minimum 0Minimum 0Minimum 0
Maximum 6107Maximum 7424.5Maximum 2241
When the means were compared between the groups 1, 2 and 3 as individual pairs there
 was no significant difference in cell counts between any of the pairs. 
We also performed a separate analysis by grouping the tumours into 
either node negative or node positive groups. Again there was no significant difference
 (p= 0.32).
3.6.2.3.5 IID and ER status
  Table 3.11: Cell count data based on ER status107
ER Negative  Count mm 2 ER Positive Count mm 2 
Mean 1127.7Mean 715.7
Standard   Error 108.3
Standard
Error 62.3
Median 899Median 480.5
Range 7393.5Range 6107
Minimum 31Minimum 0
Maximum 7424.5Maximum 6107
The mean and median cell counts per square mm were significantly greater in the ER 
negative patients. Er negative tumours had a greater IID (p < 0.0002).
 
3.7: Discussion
We recall that our hypothesis was that metastatic relapse would be less likely in women 
with breast cancers in which a significant immune infiltrate was present than in women 
with cancers in there was no significant immune-cell infiltrate. 
In keeping with the literature (Bilik et al 1989, Lee et al 2006) we found that the majority 
of the tumours studied had some evidence of an immune cell infiltrate. The range was 
wide, as illustrated in figures 3.15 an 3.16. However only 3 of the tumours in our 
data set of 270 showed absolutely no evidence of tumour infiltrating lymphocytes.
This supports previous investigations concluding that breast cancer is an immunogenic
tumour and interacts with the host immune system, provoking a response. 
In agreement with our hypothesis, we did find a statistically significant different 
between our ‘cases’ and controls. However, this difference was on average too small to
be considered biologically significant. Nevertheless, it does support the idea that host
immune responses are in some way mounting a successful response to the tumour. 108
There have been many studies over the last twenty years looking at the relationship 
between lymphocytic infiltrates in breast cancer and prognosis. The results have been 
conflicting. The most recent large study by Lee et al in 2006, aimed to establish an 
association between tumour lymphocytic infiltration and better prognosis. They examined 
the tumours of 745 patients and looked at the degree of lymphocytic infiltration. They 
established, on multivariate analysis,  that overall prognosis was better when there was 
evidence of diffuse inflammation, in tumours containing necrosis.
Prior to this there have been several studies that have concluded that there was no 
association between the inflammatory response in the the tumour and  prognosis 
(Haybittle 1982, Aaltoma 1992). Carlomagno in 1995 and Scholl in 1996 both found that 
it was associated with a worse prognosis. However many of these studies only looked at 
inflammation as one variable amongst many  and details regarding assessment of 
inflammation was limited. 
Our study was a well designed case-control study which controlled for the several factors 
with prognostic significance in breast cancer. The power calculation had estimated 
that we needed  a total of 333 patients, i.e. 111 ‘case’ and 222 controls. Unfortunately as 
we explained in the methodology section it was not possible to achieve this, however we
still did achieve more than 80% of the total suggested.
As shown in the results we went on to look at the relationship between the factors we 
controlled for and the inflammatory  infiltrate density.
Similarly to previous work (Menard et al 1997) we found no association between 
lymphocytic infiltration and age / menopausal status, although Menards group did 109
establish that the presence of a lymphocytic infiltrate was associated with improved 
survival in those under the age of  40. Although several authors (Macchetti et al 
2006, Wernicke et al 2003) have found an association between the presence of CD 4+ T 
cells within the tumour and lymph node metastases, we found no such association
 between IID and this most important of prognostic factors.
The only significant findings, in our study, in relation to prognostic factors, were of a 
greater IID in tumours of higher grade and also in those tumours that were ER negative.
 Lee et al in 2006 found that there was an increasing intensity of diffuse inflammation 
within the tumour, in those of higher histological grade. They also found that diffuse
inflammation was a marker of better prognosis in those with grade 3 tumours. This would
suggest that higher grade, or more aggressive, tumours are stimulating a more intense 
host inflammatory response, perhaps in an attempt to eradicate it.
Recently a small Brazilian study by Macchetti et al (2006) found an association between 
the presence of CD 4 + T cells within the tumour and lymph node metastases. This was in 
keeping with findings of other authors (Wernicke et al 2003).
We have confirmed that breast tumours are clearly interacting with the host immune 
response in some way as is evidenced by the very presence of tumour infiltrating 
lymphocytes. We have also shown that this is a positive response, which can impact on 
outcome.
Further studies quantifying the lymphocytic infiltrate without phenotypic evaluation of 
these cells are unlikely to be of significant value. We now need to identify what cells are 110
contributing to this response and the mechanisms of how they are defending the host. We 
now have a well designed dataset on which to do this and this will be where future work 
will be focused.
Chapter 4    The Future
4.1 Overview
Increasingly, it is recognised that the immune system has a significant
role to play in tumour development, and subsequently outcome. Research, 
particularly, during the last decade indicates that the host immune response 
to a tumour is influenced by the type of response initiated. This is illustrated 
in figure 4.1 which documents the contrasting roles of different types of 
lymphocytes.
On the one hand Th 1 CD4 and CD 8 T cells, during the acute inflammatory 
response, may initiate tumour rejection via pathways referred to in chapter 111
1. Conversely in chronic inflammation, Th2 CD4 T cells in conjunction with 
T- reg cells can suppress the cytolytic ability of the CD8 T cells.
It has become apparent that the extent of the total lymphocyte density in 
breast cancer, in itself, is perhaps not of significance without the knowledge
of the phenotype of these cells.
In our study examining the intensity of the lymphocytic infiltrate, in multiple 
breast cancers, we have helped to confirm this by demonstrating there is a greater 
lymphocytic infiltrate in those tumours that do not progress to metastatic disease.
Figure 4.1 Contrasting roles of adaptive lymphocytes during tumour development.
DeNardo and Coussens Breast Cancer Research, 2007112
We see in figure 4.1 the significance of knowing the types of inflammatory 
cells taking part in the host response to the presence of a tumour. Now that we know 
that the inflammatory response in breast cancer is significant in
predicting survival, we can focus on eliciting more information about it.
If we are to be able to manipulate the response that is occurring we need to identify the
individual cells and demonstrate the extent to which they can influence outcome.
The role of the immune system in cancer development is complex. We have 
clearly shown in our study, that the majority of breast cancers exhibit
evidence of an immune response as reflected by the lymphocytic infiltrate, 
however variable the extent of this is. It is accepted that chronic infiltration 
of  human tissue by some innate immune cell types, such as monocytes and 
macrophages, is associated with the development of epithelial cell cancers 
(Coussens et al 2002).
So where does this leave us in trying to develop better, specifically immune based
treatments for breast cancer? We must remember that in spite of improved prognosis, the 
overall mortality from breast cancer is still significant. Metastatic disease remains 
incurable.
 There have been improvements over recent years, not least from the recent 
introduction of Herceptin, the recombinant humanized anti-HER2 monoclonal antibody 
trastuzumab, to the physician’s armament. Preclinical models demonstrated that this 113
antibody has significant anti-tumor activity as a single agent and has synergy with 
certain chemotherapeutic drugs. Phase II and III clinical trials performed in women with 
metastatic breast cancer that overexpress HER2 have shown that trastuzumab has 
clinical activity when used as first-, second- or third-line monotherapy, and improves
survival when used as first-line therapy in combination with chemotherapy(Slamon et al 
2001).The anticancer effects of these antibodies, is mediated as we previously discussed 
via antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity 
(Naylor et al 2001). Monoclonal antibodies have emerged as a class of novel oncology
therapeutics. Many are being developed and as many as three different solid tumours, in 
addition to breast cancer, have antibodies licensed for use in clinical treatment. They 
include Bevacizumab for both colorectal and lung cancer (Yan 2008).
We recall that the concept of using antibodies as “magic bullets” to specifically attack
 malignant tumor cells was originally proposed by Ehrlich 1 at the beginning of the 20th 
century. Almost a century later, in spite of varying success along the way we are again 
focusing on this theory. 
Active immunotherapy is still an investigational approach to the treatment of breast 
cancer. In general, active immunization of those with cancer, using tumour specific 
antigen vaccine does not  induce regression or cure. It is possible that success will be
 from using cancer vaccines as a preventative measure, of either primary disease or 
recurrence. Active immunization of cancer patients with HER-2/neu helper peptide
vaccines can boost antigen-specific T cell frequencies in vivo (Knutson et al 2001).
Because of the heterogeneous nature of solid tumours, vaccines that can act against 114
several different cancer antigens may be necessary. We know that tumours escape 
immune surveillance via a number of mechanisms including loss of cancer antigens and 
MHC- 1 expression (Jager et al 2002 &1997). Future studies will need to focus on 
vaccine use in the adjuvant setting where tumour heterogenicity and  immune escape may 
not yet have developed (Jager et al 2005). Combining vaccines with monoclonal 
antibodies in addition to standard adjuvant therapy may be necessary.
Immunomonitoring is an essential component of the development of immunotherapy.
Another area of focus in recent years has been the systemic inflammatory response.
Al Murri et al (2006) found that the systemic inflammatory response, as evidenced by 
elevated circulating concentrations of C-reactive protein(CRP) and hypo-albuminaemia, 
was independently associated with decreased survival in breast cancer patients with
advanced disease. There is also some evidence that these acute-phase proteins have
 independent prognostic value in primary breast cancer (Lis et al 2006, Al Murri et al
 2007). So is there any relationship between this systemic response and the local one?
A recent study by Al Murri et al(2008) found a positive association between an elevated
CRP and the presence of CD4+ T cells in a group of patients with primary operable
breast cancer. However no association between CRP, or tumour infiltration by T 
lymphocytes, and survival was found. Their findings would suggest that there is that 
there is a connection between the local and systemic responses. This may be important 
when considering new therapies. For example it is well recognized in colon cancer that 
inflammatory diseases of the colon increase the risk of colorectal cancer (Rhodes and 115
Campbell 2002) and there is some evidence that the use of nonsteroidal anti-
inflammatory drugs may protect against colon cancer (Gupta and Dubois 2001). As is the
case with breast cancer an elevated CRP is associated with decreased survival in those
with colorectal cancer.
It may be possible for us to look at this in the future on our dataset of patients and 
correlate it with the local response.
4.2 Conclusion
In conclusion it would seem that the inflammatory response in breast cancer does have a 
role to play in the development of the disease and that those tumours which do not 
metastasise are more likely to have evidence of this response. We also have established a 
way to accurately and practically measure this on immunohistochemistry .
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Appendix A. 
Algorithm for counting TILs
1. Immunostain sections in one batch using automation if available. 
2. Capture ten  40 digital images of fields for counting, using the same microscope, 
camera, and light intensity. Save as RGB tif files. Do not use lossy file compression.
3. Open a representative image in Photoshop. Use ‘Colour Picker’ tool to choose a 
Foreground Colour equal to mid-range DAB staining. Note RGB and Lab values 
corresponding to this colour, so you can reset it later if need be.
4. Open ‘Colour Range’ tool. Set ‘Fuzziness’ to 100. Verify that these settings choose 
pixels corresponding to the DAB staining. Adjust Foreground Colour and Fuzziness until 
satisfied with selection.
5. With these settings (check), open each file in turn; apply the Colour Range tool; 
confirm that the selection looks right; and record the number of pixels selected from the 
Image/Histogram dialogue in an spreadsheet.
6. For each set of 10 images, open again the two images with the most labelled pixels.
7. If these images do not include too many DAB labelled cells, count the total number of 
cells. If there are too many to count them all, select an area containing a countable 
number of cells. Count them. Then count the number of signal pixels in this area by 
applying the Colour Range tool to this area only.
8. Calculate the average number of labelled pixels per cell over these two images.
9. Use this calibration to calculate the number of labelled cells in all 10 images.
10. Convert to cells per mm2 (using image size measurements).
Appendix B
ID MENO SIZE GRADE NODES ER COUNT PerMMSq
16POST 60 2 4POS 30 46.5
234PRE 55 3 2NEG 50 135
252POST 40 2 0POS 190 294.5
334POST 30 2 12POS 360 558
339POST 12 2 2POS 100 270
349POST 11 2 0NEG 640 992141
352POST 25 2 1POS 430 666.5
359POST 20 2 5POS 130 201.5
365PRE 17 3 0POS 140 217
399POST 12 2 1POS 20 54
431POST 24 3 1NEG 650 1007.5
432PRE 20 3 1NEG 60 93
460POST 20 2 0POS 170 263.5
473PRE 12 3 2NEG 860 1333
474POST 25 2 0POS 390 604.5
617POST 30 2 7POS 430 666.5
622POST 20 3 11NEG 670 1038.5
651PRE 19 3 1POS 370 573.5
673PRE 17 2 13POS 1160 1798
684PRE 17 3 0NEG 270 418.5
690POST 25 1 17POS 370 573.5
696POST 17 2 3POS 250 387.5
702PRE 15 3 0POS 450 697.5
729POST 40 2 0NEG 580 899
730POST 17 3 0POS 70 108.5
755POST 16 3 0NEG 560 868
757POST 22 3 5POS 0 0
781PRE 14 3 0NEG 510 1377
782POST 20 3 0POS 130 201.5
806POST 21 3 4NEG 770 1193.5
819PRE 21 2 0NEG 830 1286.5
820POST 35 2 1POS 190 294.5
853PRE 30 3 2NEG 370 573.5
863POST 20 3 2POS 210 325.5
867PRE 17 2 1POS 120 186
869PRE 20 2 1POS 440 682
880POST 13 2 3POS 260 403
1018POST 20 2 2POS 240 372
1019POST 12 3 2POS 660 1023
1034POST 24 2 1POS 140 217
1042POST 29 3 2NEG 110 170.5
1054POST 32 3 0NEG 650 1007.5
1061PRE 30 3 2POS 160 248
1076POST 8 2 4POS 140 217
1105POST 35 2 0POS 160 248
1151POST 11 2 0NEG 700 1085
1257POST 17 3 5POS 830 2241
1315POST 30 3 1NEG 1770 4779
1318PRE 15 2 0POS 350 542.5
1420POST 32 2 2POS 160 248
1431POST 25 2 0POS 470 728.5
1439POST 17 1 0POS 210 567
1440PRE 17 3 0NEG 330 891
1444POST 25 1 17POS 300 810
1446POST 20 2 0POS 160 432
1483POST 20 3 1NEG 470 1269142
1505PRE 25 3 2NEG 460 1242
1513POST 26 2 2POS 210 325.5
1516PRE 20 2 2NEG 840 1302
1563PRE 20 3 0NEG 130 201.5
1670PRE 20 3 0NEG 250 387.5
1709POST 4 3 3POS 1290 1999.5
1721POST 5 3 0NEG 1750 2712.5
1785POST 30 2 9POS 430 666.5
1794POST 35 2 2POS 70 108.5
1797PRE 15 3 2NEG 230 356.5
1801PRE 20 3 0NEG 540 1458
1803PRE 40 3 0POS 390 1053
1805PRE 36 2 5NEG 140 378
1806POST 20 2 1POS 100 155
1834POST 45 2 0POS 490 1323
1899POST 15 2 1NEG 840 1302
1927POST 22 3 0NEG 650 1007.5
1981POST 25 3 0POS 1580 2449
2006POST 15 3 2NEG 500 775
2012POST 30 3 1NEG 510 790.5
2034PRE 12 1 1POS 920 1426
2314POST 19 2 0POS 30 46.5
2341PRE 35 2 2POS 1030 1596.5
2358POST 40 2 16POS 120 186
2443PRE 13 2 1POS 120 186
2980POST 35 2 0POS 0 0
2981POST 35 2 0POS 20 54
3333PRE 20 3 1NEG 1450 2247.5
3458POST 14 2 0POS 1460 2263
4454POST 20 3 0POS 790 1224.5
4480POST 28 3 4POS 230 356.5
4496PRE 20 3 2POS 220 594
4499POST 35 2 0NEG 740 1147
A POST 20 3 0NEG 580 899
ID MENO SIZE GRADE NODES ER COUNT PerMMSq
3193POST 50 2 19POS 1260 1953
3357PRE 55 3 1NEG 770 2079
549POST 25 2 0POS 740 1147
1522POST 25 2 12POS 160 248
871POST 10 2 2POS 150 232.5
1332POST 6 2 0NEG 50 77.5
788POST 15 2 1POS 310 480.5
1346POST 25 2 5POS 60 93
1831PRE 8 3 0POS 610 945.5
260POST 5 2 1POS 130 201.5
718POST 25 3 2NEG 160 248
775PRE 20 3 1NEG 1960 3038
563POST 25 2 0POS 160 248143
3514PRE 12 3 2NEG 430 1161
1339POST 25 2 0POS 860 1333
1101POST 35 2 5POS 180 279
1348POST 20 3 13NEG 1002 1553.1
799PRE 19 3 1POS 610 945.5
§ PRE 22 2 6POS 230 356.5
351PRE 12 3 0NEG 520 806
1011POST 15 1 10POS 650 1007.5
1082POST 8 2 1POS 560 868
1022PRE 18 3 0POS 500 1350
384POST 30 2 0NEG 30 81
1605POST 18 3 0POS 740 1147
774POST 8 3 0NEG 820 1271
X POST 30 3 7POS 810 1255.5
1424PRE 10 3 0NEG 570 1539
2004POST 20 3 0POS 310 480.5
792POST 23 3 6NEG 410 635.5
293PRE 21 2 0NEG 20 31
196POST 35 2 1POS 510 790.5
343PRE 28 3 2NEG 80 216
1562POST 40 3 1POS 300 465
1157PRE 8 2 2POS 140 217
1844PRE 20 2 1POS 1100 2970
64POST 16 2 1POS 650 1007.5
1610POST 17 2 1POS 120 186
1006POST 18 3 1POS 190 294.5
1114POST 25 2 1POS 3310 5130.5
546POST 20 3 1NEG 1090 1689.5
1783POST 20 3 0NEG 50 77.5
791PRE 20 3 2POS 750 1162.5
1669POST 18 2 15POS 320 496
4473POST 42 2 0POS 290 449.5
1461POST 11 2 0NEG 100 270
1253POST 18 3 6POS 60 162
2745POST 20 3 1NEG 1050 1627.5
1781PRE 18 2 0POS 250 387.5
1087POST 20 2 1POS 480 744
1099POST 35 2 0POS 100 155
2124POST 11 1 0POS 280 434
1662PRE 18 3 0NEG 1280 1984
1013POST 20 1 8POS 330 511.5
672POST 20 2 0POS 130 201.5
828POST 25 3 1NEG 880 1364
1939PRE 20 3 3NEG 50 77.5
1880POST 22 2 1POS 0 0
1128PRE 30 2 1NEG 100 155
542PRE 20 3 0NEG 920 1426
789PRE 35 3 0NEG 680 1054
1841POST 16 3 1POS 710 1917
1142POST 7 3 0NEG 420 651144
110POST 40 2 10POS 500 775
1552POST 40 2 3POS 480 1296
437PRE 12 3 2NEG 220 341
941PRE 28 3 0NEG 1350 2092.5
719PRE 25 3 0POS 240 372
2769PRE 30 2 4NEG 430 666.5
4474POST 25 2 2POS 430 666.5
1631POST 22 2 0POS 330 891
1164POST 9 2 3NEG 1330 2061.5
1423POST 38 3 0NEG 900 1395
23POST 24 3 0POS 1160 1798
2748POST 10 3 2NEG 400 620
660POST 40 3 1NEG 260 403
1538PRE 12 1 1POS 70 108.5
112POST 19 2 0POS 260 403
797PRE 20 2 2POS 920 1426
2951POST 30 2 16POS 680 1836
813PRE 15 2 2POS 770 1193.5
617POST 30 2 0POS 350 542.5
1438POST 21 2 0POS 940 2538
3004PRE 5 3 1NEG 630 976.5
368POST 12 2 0POS 280 434
671POST 20 3 0POS 650 1007.5
2364POST 35 3 10POS 80 124
243PRE 42 3 3POS 210 567
367POST 25 2 0NEG 1770 2743.5
1459POST 30 3 0NEG 370 573.5
ID MENO SIZE GRADE NODES ER COUNT PerMMSq
2335POST 50 2 9POS 430 1161
1116PRE 50 3 2NEG 490 759.5
475POST 25 2 0POS 110 170.5
556POST 25 2 13POS 250 387.5
798POST 10 2 1POS 100 270
680POST 10 2 0NEG 230 356.5
937POST 20 2 1POS 90 139.5
579POST 35 2 6POS 490 1323
1851PRE 10 3 0POS 890 1379.5
1639POST 10 2 1POS 170 263.5
26POST 20 3 1NEG 4790 7424.5
1092PRE 38 3 1NEG 790 1224.5
1480POST 25 2 0POS 100 155
2142PRE 16 3 2NEG 1040 1612
1091POST 22 2 0POS 910 1410.5
1174POST 24 2 6POS 60 162
355POST 30 3 10NEG 300 465
1073PRE 15 3 1POS 280 434
1116PRE 50 3 2NEG 490 759.5
1260PRE 10 3 0NEG 2950 4572.5
623POST 18 1 7POS 450 697.5145
1324POST 15 2 1POS 160 248
1007PRE 16 3 0POS 240 372
1025POST 20 2 0NEG 130 201.5
340POST 15 3 0POS 460 713
1460POST 15 3 0NEG 1950 3022.5
Y POST 37 3 6POS 850 1317.5
1023PRE 10 3 0NEG 980 1519
194POST 20 3 0POS 310 837
1141POST 23 3 4NEG 1340 2077
1378PRE 22 2 0NEG 510 790.5
1712POST 28 2 1POS 40 62
2262PRE 22 3 1NEG 840 1302
2548POST 23 3 1POS 250 387.5
382PRE 15 2 1POS 580 899
268PRE 30 2 3POS 440 682
1033POST 15 2 2POS 1100 1705
341POST 18 2 1POS 130 201.5
662POST 12 3 3POS 230 356.5
459POST 20 2 1POS 1300 2015
796POST 40 3 3NEG 190 513
1790POST 25 3 0NEG 400 620
1913PRE 35 3 1POS 650 1007.5
1043POST 15 2 5POS 510 790.5
4497POST 42 2 0POS 250 387.5
1606POST 15 2 0NEG 180 279
732POST 18 3 9POS 210 325.5
2929POST 25 3 3NEG 330 891
488PRE 7 2 0POS 10 15.5
61POST 35 2 1POS 670 1038.5
762POST 22 2 0POS 190 294.5
804POST 6 1 0POS 3940 6107
1662PRE 18 3 0NEG 1280 1984
1325POST 20 1 4POS 90 139.5
1711POST 20 2 0POS 170 459
354POST 26 3 1NEG 320 496
1536PRE 35 3 1NEG 120 186
697POST 40 2 3POS 360 558
786PRE 25 2 3NEG 150 232.5
140PRE 12 3 0NEG 580 899
1014PRE 25 3 0NEG 190 294.5
1961POST 15 3 2POS 540 837
1323POST 14 3 0NEG 310 480.5
1070POST 23 2 8POS 190 294.5
1326POST 20 2 1POS 270 418.5
1010PRE 19 3 2NEG 270 418.5
1437PRE 25 3 0NEG 70 108.5
1473PRE 45 3 0POS 720 1116
1158PRE 50 2 8NEG 350 542.5
821POST 20 2 1POS 1950 3022.5
1012POST 30 2 0POS 290 783146
560POST 10 2 2NEG 170 263.5
536POST 28 3 0NEG 270 418.5
1321POST 20 3 0POS 280 434
3725POST 18 3 2NEG 190 294.5
2108POST 25 3 2NEG 750 2025
736PRE 8 1 1POS 280 434
614POST 15 2 0POS 480 744
812PRE 20 2 2POS 10 15.5
2138POST 23 2 4POS 440 682
1074PRE 12 2 1POS 220 341
472POST 40 2 0POS 390 604.5
1173POST 30 2 0POS 450 1215
3320PRE 15 3 1NEG 1790 2774.5
69POST 12 2 0POS 590 914.5
949POST 30 3 0POS 30 81
3332POST 36 3 5POS 120 186
480PRE 37 3 2POS 40 108
855POST 25 2 0NEG 1800 2790
357POST 20 3 0NEG 1020 1581
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